TITLE PAGE
Protocol Title: A Single Arm Multiple Dose Study to Assess the E fficacy and Safety
of ANB019 in Subjects with Generalized Pustular Psoriasis
Protocol Number: ANB019-[ADDRESS_294323]: ANB019
Study Phase: 2aSponsor Name: [CONTACT_242694] .
Legal Registered Address: 
[ADDRESS_294324],
San Diego, CA [ZIP_CODE], [LOCATION_002]
Regulatory Agency Identifying Number(s):
Investigational New Drug (IND) number: 136145
National Clinical Trial (NCT) number:
NCT 03619902
European Clinical Trials Database (EudraCT) Number: 
2017-004021-33
Date of Protocol: [ADDRESS_294325] and review 
by a Regulatory Authority as required by [CONTACT_242673] d regulations, without the written 
authorization of AnaptysBio, Inc. These restrictions will conti nue to apply after the study has closed.
CONFIDENTIAL Protocol ANB019-002 –Amendment 5
29 October 2019 3INVESTIGATOR SIGNATURE [CONTACT_1783]:
I confirm that I have read and a pproved this protocol in its en tirety and will comply with the 
obligations as detailed in all applicable regulations and guide lines (eg, ICH GCP guidelines) and 
the protocol.
Name 
 [CONTACT_242733]019-002 –Amendment 5
29 October 2019 4TABLE OF CONTENTS
INVESTIGATOR SIGNATURE [CONTACT_1783]: ................................... ...........................................3  
TABLE OF CONTENTS .............................................. ..........................................................4  
TABLE OF TABLES................................................ ............................................................... 7 
1.0 PROTOCOL SUMMARY ............................................... ...........................................8  
1.1 Synopsis....................................................... ......................................................8  
1.2 Study Schema ................................................... ..............................................12  
1.3 Schedule of Activities......................................... ............................................13  
2.0 INTRODUCTION................................................... ...................................................16  
2.1 Study Rationale ................................................ ..............................................16  
2.2 Background ..................................................... ...............................................17  
2.2.1  Nonclinical Studies............................................ ................................17  
2.2.2  Clinical Studies............................................... ...................................18  
2.3 Benefit/Risk Assessment........................................ ........................................19  
3.0 OBJECTIVES AND ENDPOINTS ....................................... ...................................22  
4.0 STUDY DESIGN................................................... .....................................................24  
4.1 Overall Design ................................................. ...............................................24  
4.2 Scientific Rationale for Study Design.......................... .................................25  
4.3 Justification for Dose ......................................... ............................................25  
4.4 End of Study Definition........................................ .........................................25  
4.5 Study Stoppi[INVESTIGATOR_2121] ........................................ ........................................25  
4.5.1  Stoppi[INVESTIGATOR_242647]...................... ....................25  
4.5.2  Criteria for Stoppi[INVESTIGATOR_178144]................................ ..........................26  
5.0 STUDY POPULATION ............................................... .............................................27  
5.1 Inclusion Criteria............................................. ..............................................27  
5.2 Exclusion Criteria ............................................. .............................................28  
5.3 Lifestyle Considerations ....................................... .........................................30  
5.4 Screen Failures ................................................ ...............................................30  
6.0 STUDY TREATMENT ................................................ .............................................32  
6.1 Study Treatment Administered................................... .................................32  
6.2 Preparation/Handling/Storage/Accountability .................... .......................33  
6.3 Measures to Minimize Bias: Randomization and Blinding.......... ..............34  
6.4 Study Treatment Compliance..................................... ..................................34  
6.5 Concomitant Therapy............................................ ........................................34  
CONFIDENTIAL Protocol ANB019-002 –Amendment [ADDRESS_294326] 
DISCONTINUATION/WITHDRAWAL ..................................... ...........................[ADDRESS_294327] Discontinuation/Withdrawal from the Study.............. ..................[ADDRESS_294328] to Follow-up .............................................. .............................................37  
8.0 STUDY ASSESSMENTS AND PROCEDURES ............................... .....................38  
8.1 Efficacy Assessments ........................................... ..........................................38  
8.1.1  Clinical Global Impression..................................... ...........................38  
8.1.2  Modified Japanese Dermatol ogy Association (JDA) Severity 
Index .......................................................... ........................................38  
8.1.3  Psoriasis Area Severity Index (Only in Subjects With PP)....... ........39  
8.1.4  Generalized Pustular Pso riasis Physician’s Global 
Assessment Scale............................................... ................................[ADDRESS_294329]............................. .......................43  
8.3.7  Infusion-related Adverse Events ................................ .......................43  
8.3.8  Disease-related Events and/or Disease-related Outcomes Not 
Qualifying as AEs or SAEs ...................................... .........................44  
8.4 Treatment of Overdose.......................................... ........................................44  
8.5 Pharmacokinetics............................................... ............................................45  
8.6 Pharmacodynamics............................................... .........................................46  
8.7 Genetics....................................................... ....................................................46  
8.8 Biomarkers ..................................................... ................................................46  
CONFIDENTIAL Protocol ANB019-002 –Amendment [ADDRESS_294330] Characteristics and Medical History ..................... ...............49  
9.4.3  Concomitant Medication ......................................... ..........................50  
9.4.4  Efficacy Analyses.............................................. ................................50  
9.4.5  Safety Analyses ................................................ .................................51  
9.4.6  Immunogenicity Analyses ........................................ .........................52  
9.4.7  Pharmacokinetic/Pharmac odynamic Analyses....................... ...........53  
9.4.8  Exploratory Biomarker Analyses ................................. .....................53  
9.4.9  Missing Data................................................... ...................................54  
9.5 Interim and Final Analyses..................................... ......................................54  
10.0  REFERENCES..................................................... ......................................................55  
11.0  APPENDICES..................................................... .......................................................57  
Appendix 1  Abbreviations.................................................. .................................58  
Appendix 2  Regulatory, Ethical, and Study Oversight Considerations........ ..60 
Appendix 3  Clinical Laboratory Tests ...................................... .........................67  
Appendix 4  Adverse Events: Definitions and Procedures for 
Recording, Evaluating, Foll ow-up, and Reporting................ .....................69  
Appendix 5  Excluded Medications/Therapy ................................... ..................73  
Appendix 6  Contraceptive Guidance and Collection of Pregnancy 
Information.................................................... .................................................74  
Appendix 7  Genetics ....................................................... .....................................78  
Appendix 8  Clinical Global Impression ..................................... ........................79  
Appendix 9  Modified Japanese Dermatological Association (JDA) 
Severity Index................................................. ................................................80  
Appendix 10  Psoriasis Area Severity Index Score (PASI) ..................... ............81  
Appendix 11  Generalized Pustular Psoriasis Physician Global 
Assessment Scale ............................................... .............................................82  
Appendix 12  Dermatology Life Quality Index ................................. ...................83  
Appendix 13  Summary of Changes ............................................. .........................85  
CONFIDENTIAL Protocol ANB019-002 –Amendment 5
29 October 2019 7TABLE OF TABLES
Table 1  Study Treatment Details ........................................ ..........................................33  
Table 2  PK/ADA Sample Collection and Timepoints........................ ..........................[ADDRESS_294331] of Excluded Medications ................................... .......................................73  
CONFIDENTIAL Protocol ANB019-002 –Amendment 5
29 October 2019 81.0 PROTOCOL SUMMARY
1.1 Synopsis
Protocol Title: A Single Arm Multiple Dose Study to Assess the Efficacy and Safet y of ANB019 in 
Subjects with Generalized Pustular Psoriasis
Rationale:
This study is designed to evaluate the efficacy and safety of m ultiple doses of ANB019 in subjects with 
generalized pustular psoriasis (GPP). Generalized pustular psor iasis is a severe, debilitating, and 
life-threatening systemic inflammatory disease ( Marrakchi 2011, Benjegerdes 2016 ). The interleukin-36
(IL-36) pathway, by [CONTACT_242674], has been s hown to play a key role in 
pathogenesis of GPP.
In individuals with a normal IL-36/interleukin-36 receptor (IL- 36R) axis, the action of the IL-[ADDRESS_294332] identified IL-36RN mutations, the gene cod ing for IL-36Ra, in a subset of GPP 
patients (Marrakchi 2011; Onoufriadis 2011; Sugiura 2012; Capon 2013, Na varini 2017) . These mutations 
disrupt the inhibitory function of IL-36Ra, leading to uncontro lled IL-36R activation. Other genetic 
defects have also been associated with GPP, including mutations  in the AP1S3 and CARD14 genes (Mahil 
2016; Jordan 2012; Farooq 2013 ). Regardless of the presence of known mutations, activation of IL-[ADDRESS_294333] limited 
efficacy in GPP ( Benjegerdes 2016) . The investigational product, ANB019, is a monoclonal antibody
(mAb) that specifically binds to IL-36R and antagonizes IL-[ADDRESS_294334] in patients with GPP. The inf ormation obtained from this study may 
provide important insights into potential new treatment options for GPP.
CONFIDENTIAL Protocol ANB019-002 –Amendment [ADDRESS_294335] ’s disease activity (response to study treatment) will be evaluated  using the CGI, JDA, GPPPGA
scale, total BSA, DLQI, and PASI (if plaque psoriasis is present) (O ji 2015; Navarini 2017).
Serum samples for PK and immunogenicity will be collected prior to administration of ANB019 and at 
the other time points specified in the Schedule of Activities ( see Section 1.3). In addition, blood samples 
for genetic analysis and a punch biopsy will also be taken durin g the study. All subjects enrolled in the 
study will be asked to participate in the skin biopsy and/or gen etic analysis; however, subject participation 
is optional.
Safety assessments including AE/SAE monitoring, vital signs, ph ysical examination, ECGs, laboratory 
measurements, and urine assessm ents will be performed during th e study period.
The End of Study (EOS) Visit will be on Day 169 and all subjects wi ll return to the study center for the 
EOS procedures (see Section 1.3).
Number of Investigators and Study Centers:
Approximately 8-10 Investigators and 8-10 study  centers are expected to particip ate in this study.
Number of Subjects:
The sample size is not based on statistical power consideration s.
Approximately 10 subjects will be enrolled at 8-10 study centers.
Treatment Groups and Duration:
The study will have a screening period of up to 42 days (6 weeks), treatment period of 12 weeks, and
follow-up period of 12 weeks.
Eligible subjects will receive 750 mg IV (1-hour duration) of ANB0 19 in an open-label manner in 
polyvinyl chloride or polyolefin bags following dilution to a t otal volume of 100 mL with 0.9% sodium 
chloride followed by 3 doses of 100 mg SC administered on Days 29 , 57, and 85.
Statistical Methods:
The default summary statistics for continuous variables include s number of contributing observations (n), 
mean, standard deviation (SD), median, minimum, and maximum.
For categorical variables, the number and percentage (the perce ntage of subjects in each category relative 
to the total number of subjects in the relevant analysis populat ion or relative to the total number of 
subjects in the relevant analysis population, with assessments a vailable [where appropriate]) in each 
category will be the default summary presentation.
For primary and secondary continuou s endpoints, change from Bas eline will be evaluated where possible. 
Actual and change in data from baseline will be summarized descr iptively for each treatment.
CONFIDENTIAL Protocol ANB019-002 –Amendment 5
29 October 2019 12Frequency and percentages for each response Yes/No will be pres ented separately by [CONTACT_765]. A shift table 
of change from Baseline to EOS will be displayed for each score.
For safety and tolerability, AEs, SAEs, vital signs, physical e xaminations, and laboratory assessments at 
specific time points will be evaluated. All safety data will be  summarized descriptively. Number and 
percentage of AEs will be presented for each treatment by [CONTACT_242675] (MedDRA) dictionary. Individual listings of all 
SAEs and AEs leading to discontinuation from the study drug will  be summarized using the current 
MedDRA dictionary. Similar analyses will be performed for poten tial significance and clinical 
importance of AEs.
Summaries and listings of data for vital signs, hematology, bio chemistry, and urinalysis laboratory tests 
will be presented. Appropriate descriptive statistics will be s ummarized for the observed value at each 
scheduled assessment and for the c orresponding change from Base line. Baseline will be the last 
assessment before ANB019 dosing.
The PK of ANB019 will be evaluated by [CONTACT_242676]. These drug 
concentrations will be listed and summarized for each sampling time point using appropriate 
descriptive statistics. The PK parameters will be summarized us ing appropriate descriptive 
statistics. Attainment of steady state will be graphically evalu ated over the sampling period for 
the IV/SC treatment regimen.
An interim analysis will be perfor med when approximately 50% of subjects have completed their 
Week [ADDRESS_294336] reached 16 weeks p ostdosing. The interim analysis 
will assess primary efficacy and all safety data.
1.2 Study Schema
Abbreviations: BSL = baseline; IV = intravenous, SC = subcutaneou s.

CONFIDENTIAL Protocol ANB019-002 –Amendment 5
29 October 2019 131.3 Schedule of Activities
Screening
Period Treatment Period Follow-up Period
Procedure(up
to-42day
s prior to 
D1/W-0)D1
W0D3
W1D8
W1D15
(±1)
W2D22
(±1)
W3D29
(±2)
W4D36
(±2)
W5aD43
(±2)
W6D50
(±2)
W7aD57
(±2)
W8D64
(±2)
W9aD71
(±2)
W10D78
(±2)
W11aD85
(±2)
W12D113
(±2)
W16D141
(±2)
W20D169
(±2)
W24 /EOS/
ETb
Informed consent X
Inclusion/exclusion 
criteriaX X
Medical history and prior 
medicationsX
Heightcand weight X X
CGIjX X X X X X X X X X X X
Modified JDA, DLQId,nX X X X X X X X X X X X X X
GPPPGAdX X X X X X X X X X X X X X
PASI if plaque psoriasis is 
presentd,n X X X X X X X X X X X X X X
Serum cytokineslX X X X X X X X
Complete physical 
examinatione,l X X X X X X X
12-lead electrocardiogramfX X X X X
Vital signsgX X X X X X X X X X X X X X
Safety laboratory testingh,lX X X X X X X X X X X X X X
Quantiferon®-TB Gold 
Testh,l X
Virologyh,lX
Chest x-raynX
Urinalysish,lX X X X X X X
CONFIDENTIAL Protocol ANB019-002 –Amendment 5
29 October 2019 14Screening
Period Treatment Period Follow-up Period
Procedure(up to -
42days 
prior to 
D1/W-0)D1
W0D 3
W1D8
W1D15
(±1)
W2D22
(±1)
W3D29
(±2)
W4D36
(±2)
W5aD43
(±2)
W6D50
(±2)
W7aD57
(±2)
W8D64
(±2)
W9aD71
(±2)
W10D78
(±2)
W11aD85
(±2)
W12D113
(±2)
W16D141
(±2)
W20D169
(±2)
W24/EOS
/ETb
Serum pregnancy testhX X
Urine pregnancy test
(WOCBP only)hX X X X X X
FSH ( postmenopausal 
woman aged over [ADDRESS_294337] 1 year of amenorrhea only)
hX
Samples for PKj,lX X X X X X X X X X X X X
Skin biopsieskX X
Photography X X X
Whole blood for DNA 
samplingm Xj,k
Whole blood for mRNA 
samplingm Xj,kXk
Blood collection for 
ADAn X X X X X
Telephone contact [INVESTIGATOR_13701] X X X X
ANB019 administrationoX X X X
AEsX X X X X X X X X X X X X X X X X X
Concomitant m edication XoX X X X X X X X X X X X X X X X X
Abbreviations: ADA = anti-drug antibody; AE = adverse event; BSA = bod y surface area; CGI = Clinical Global Impression; D = day; DLQI = Der matology 
Life Quality Index; ECG = electrocardiogram; EOS = end of study; ET = early termination, FSH = follicle stimulating hormone; ICF = Infor med consent form; 
PASI = Psoriasis Area Severity Index; JDA = Japanese Dermatology As sociation; PK = pharmacokinetics; QoL = Quality of Life; SAE = seriou s adverse event; 
TB = tuberculosis; W = week; WOCBP = Woman of childbearing potential.
CONFIDENTIAL Protocol ANB019-002 –Amendment [ADDRESS_294338] will be encoura ged to return to the study center for the ET/EOS visit (Week 24/ Day 169).
c. Height to be measured at Screening only.
d. Refer to Section 8.1for details and instructions regarding CGI, JDA, PASI, total BSA as measured by [CONTACT_242677], GPPPGA, and QoL questionnaire 
(DLQI). The QoL questionnaire should be the first assessment co mpleted by [CONTACT_242678]. At the screening visit, the ICF should be signed prior to QoL questionnaire and ot her study related assessments.
e. Refer to Section 8.2.1 for details regarding complete physical examination. A complete p hysical examination will include assessments of general 
appearance; skin; head/neck; pulmonary, cardiovascular, gastroi ntestinal, external genitourinary, lymphatic, and musculoskelet al system; extremities; 
eyes (inspection and vision contr ol); nose; throat; and neurolo gic status.
f. Refer to Section 8.2.[ADDRESS_294339] and/or genetic 
analysis; however, the subject ’s participation is optional. Subjects should provide their con sent to participate in skin bio psy and genetic analysis. Punch 
biopsy will be collected on Day 1 (Normal and Psoriatic skin) an d Week 16 (psoriatic skin only).
l. Samples must be collected before study drug administration on  Day 1.
m. Optional whole blood collection for DNA and mRNA requires sep arate pharmacogenetic informed consent form (ICF).
n. On Days 1, 29, 57, and 85, all assessments should be performed  prior to study treatment administration except for the postdos e PK samples on Day 1
(Table 2). The specific order for performing the study procedure s is as follows (applicable to all visits): First QoL questionn aires then the efficacy 
assessments, vital signs, physical examination, ECG, and blood sample collection.
o. Subjects will remain in the study center for approximately [ADDRESS_294340] and second SC injections and will be  discharged as per the Investigator ’s judgment.
.
CONFIDENTIAL Protocol ANB019-002 –Amendment 5
29 October 2019 162.0 INTRODUCTION
ANB019 is a high affinity humanized IgG4 mAb that specifically b inds the interleukin-36
receptor (IL-36R) and antagonizes interleukin-36 (IL-36) signal ing. The IL-36 cytokines 
(IL-36α, IL -36β, and IL -36γ) engage with IL-36R to initiate signaling events leading to 
pro-inflammatory responses. IL-[ADDRESS_294341] that binds to IL-36R and competes with activity of I L-36 cytokines. Mutations in the
gene encoding the IL-36Ra ( IL-36RN ) result in uncontrolled activation of the IL-[ADDRESS_294342] 
leading to the development of generalized pustular psoriasis (G PP), a severe and life-threatening 
disease ( Marrakchi 2011, Benjegerdes 2016 ). As such, inhibition of IL-[ADDRESS_294343]-in-class therapy for GPP, palmoplantar pustular psoriasis (PPP), and other 
inflammatory diseases where the IL-[ADDRESS_294344] might play a patho genic role.
2.1 Study Rationale
This study is designed to evaluate the efficacy and safety of mu ltiple doses of ANB019 in 
subjects with GPP. Generalized pustular psoriasis is a severe, deb ilitating, and life-threatening 
systemic inflammatory disease ( Marrakchi 2011, Benjegerdes 2016 ). Skin lesions manifest with 
widespread sterile pustules on ery thematous skin over large BSA s. Skin rash is accompanied by 
[CONTACT_242679], general malaise, leukocytosis, elevated C-reactive protein (CRP), and frequently 
includes functional extracutaneous organ involvement that might lead to mortality ( Marrakchi 
2011 ). The IL-[ADDRESS_294345] identif ied GPP-associated IL-36RN in a 
subset of GPP patients ( Marrakchi 2011; Onoufriadis 20 11; Sugiura 2012; Capon 2013, Nav arini 
2017 ). These mutations disrupt the inhibitory function of IL-36Ra, l eading to uncontrolled 
IL-36R activation. Other genetic  defects have also been associat ed with GPP, including 
mutations in the AP1S3 and CARD14 genes ( Mahil 2016; Jordan 2012; Farooq 2013 ). Regardless 
of mutations, activation of the IL-[ADDRESS_294346] has been associate d with a sustained inflammatory 
response in pustular psoriasis suggesting a key role of IL-36 in  inflammatory skin diseases. 
Currently there is no approved therapy for GPP. Treatment optio ns are limited to existing plaque 
psoriasis (PP) and systemic immunomodulatory therapi[INVESTIGATOR_014], which have  limited and inconsistent 
efficacy ( Benjegerdes 2016) . ANB019 is an mAb that specifically binds the IL-36R and 
antagonizes IL-[ADDRESS_294347] in patients with pustular psoriasis. The information obta ined from this study is
considered important for future clinical practice as it may pro vide important insights into
potential new treatment options for GPP.
CONFIDENTIAL Protocol ANB019-002 –Amendment [ADDRESS_294348] only a few  thousand individuals. The 
prevalence of GPP has been studie d in Japan and [LOCATION_009] and repo rted as approximately 7.46 and 
1.76 cases per million of the population, respectively ( Ohkawara 1996; Augey 2006 ). Although 
GPP has been associated with psoriasis, it is considered as a d istinct disease entity based on 
different pathological pathways. Several studies have identifie d GPP-associated IL-36RN
mutations in a subset of GPP patients ( Marrakchi 2011; Onoufriadis 2011; Sugiura 2012; 
Capon 2013, Navarini 2017 ). These mutations disrupt the inhibitory function of IL-36Ra, l eading 
to uncontrolled IL-36R activatio n. While a significant proportio n of GPP cases are associated 
with deficiency of IL-36Ra, also known as DITRA, approximately 5 1% to 84% of patients
reported no mutation of the IL-36RN . Other genetic defects have also been associated with GPP, 
including mutations in the AP1S3 and CARD14 genes ( Mahil 2016; Jordan 2012; Ohkawara 
1996 ). Regardless of the presence of kn own mutations, activation of IL-[ADDRESS_294349] has been 
associated with sustained inflamma tory response in GPP suggesti ng a key role of IL-36 in 
inflammatory skin diseases.
There is no effective and approv ed treatment for GPP. Recurrent flares are common, even years 
after diagnosis (Benjegerdes 2016, Oji 2015, Navarini 2017) . Patients often require continued 
systemic immunomodulatory therapy causing significant and severe  AEs. Therefore, inhibition 
of IL-[ADDRESS_294350] and potentially offer a novel and effective treatment f or patients with GPP.
2.2.1 Nonclinical Studies
ANB019 has strong inhibitory activity of human as well as the cyno molgus monkey IL-36R. 
Nonclinical data obtained from studies with ANB019 in primary h uman and cynomolgus 
monkey cells and from in vivo non-human primate studies demonstra ted that:
xANB019 shows reactivity with human and cynomolgus monkey IL -36R ( dissociation 
constant ), but not with mouse or 
rat IL -36R.
xIn primary human and cynomolgus monkey cell populations, kerati nocytes, peripheral blood 
mononuclear cells and human whole blood, ANB019 inhibits IL-36R- mediated release of
interleukin-8 (IL-8).
xThe observed serum half-life of ANB019 in cynomolgus monkeys was  304 hours after single 
IV dose administration, and 310 hours after single SC dose admin istration at 10 mg/kg, with
CONFIDENTIAL Protocol ANB019-002 –Amendment 5
29 October 2019 18bioavailability approximately 76% consistent with the anticipat ed PK characteristics for a 
human IgG4 scaffold mAb in the monkey.
xRepeat-dose, Good Laboratory Practice toxicity and toxicokinetic  studies of [ADDRESS_294351] been co nducted with ANB019 administered by [CONTACT_242680]. There were only minor treatment-related injection site findings in 
the 4-week repeat-dose study. Tr eatment-related effects in the 13-week toxicity study 
included increased observations of nonformed feces and prolapsed  rectum, and protozoa in 
the stomachs of monkeys, the latter being consistent with the m echanism of action of an 
immune-modulator in cynomolgus monkeys ( Augey 2006 ). These studies established a no
observed adverse effect level for males at 60 mg/kg/dose adminis tered IV and for females at 
60 mg/kg/dose administered SC after [ADDRESS_294352] in human Phase I study in healthy subjects and  subjects with psoriasis has 
been conducted (ANB019-001 2018).
The Single Ascending Dose (SAD) part of the study enrolled 48 hea lthy adults and has been 
completed. Six dose levels were administered to 8 subjects in e ach cohort: 10 mg, 40 mg, 
100 mg, 300 mg, and 750 mg by [CONTACT_242681] 100 mg by [CONTACT_134087]. After single dose 
administration, ANB019 was genera lly well tolerated in male and  female healthy adults 
18-43 years old. Overall, 40 subjects (83%) experienced at least one treatment-emergent adverse 
event (TEAE). The percentage of subjects who experienced at lea st 1 TEAE was similar across 
treatment groups: 29 subjects, 81% in ANB019 group and [ADDRESS_294353] s, 92% in placebo. The most 
commonly reported AEs were upper respi[INVESTIGATOR_1092] (U RTI) (28% ANB019, 
50% placebo), headache (28% ANB019, 25% placebo), viral URTI (11% AN B019, 
8% placebo), oropharyngeal pain (8% ANB019, 0% placebo), nausea (8 % ANB019, 
0% placebo), tension headache (6% ANB019, 8% placebo), gastroenter itis (6% ANB019, 
0% placebo), herpes simplex (6% ANB019, 0% placebo), acne (6% ANB019 , 0% placebo), and 
catheter site pain (6% ANB019, 0% placebo). All other SAEs occurre d as single events. The 
majority of TEAEs were mild (73%) and moderate (26%) in severity w ith exception of [ADDRESS_294354] discontinued the 
study due to AE. There were no SAEs reported in the SAD portion of the study. No clinically 
relevant abnormalities were noted in vital signs, physical exam inations, electrocardiograms 
(ECGs), or laboratory parameters.
One subject with PP was enrolled and completed the study as per pr otocol. This subject received 
a single dose of [ADDRESS_294355] with PP in the SAD part 
of the study.
CONFIDENTIAL Protocol ANB019-002 –Amendment 5
29 October 2019 19The Multiple Ascending Dose (MAD) part of the study enrolled 24 hea lthy adults. Three dose 
levels were administered to 8 subjects in each cohort: 40 mg, 100 mg, and 300 mg by [CONTACT_242682] a week for 4 weeks. In each cohort, 6 of 8 subjects received  ANB019 and 2 subjects 
received placebo. In the MAD part of the study, 19 of 24 subjects  (79%) experienced at least 
1 TEAE. Overall, ANB019 was generally well tolerated in healthy adults (20 to 37 years old). 
The TEAEs were reported by 16 of 18 subjects (89%) in the ANB01 9 treatment group and in 
3 of 6 subjects (50%) in the placebo group following IV infusion o nce a week for [ADDRESS_294356] common TEAEs were headache (39% ANB019, 17% placebo) and upp er respi[INVESTIGATOR_4348] (17% ANB019, 17% placebo). The majority of AEs were mi ld (83%) and moderate 
(17%) in severity with no severe events reported.
There was no AE leading to study treatment withdrawal reported.  One subject developed AE of 
neutropenia [ADDRESS_294357] dose of ANB019 100 mg IV with absolute neutrophil count of 
0.7 × 109/L (previously 2.3 × 109/L on Day1, 2.1 × 109/L on Day 7, 2.0 × 109/L on Day 14, and 
2.0 × 109/L on Day 21). The subject was completely well and asymptomatic with no recent 
illness reported. All other laboratory parameters were normal. The absolute neutrophil count
returned to within the normal range 4 days later (3.1 × 109/L) and the subject completed the 
study. The AE was assessed by [CONTACT_242683].
There were no SAEs reported in the MAD part of the study. No mean ingful trends were 
observed in vital signs, physical examinations, ECGs, or laborato ry parameters.
The PK data generated after either a single or multiple IV dose administration indicated linear 
PK with area under the concentration -time curve (AUC) increasing in a generally dose 
proportionate manner . The mean m aximum observed concentration (Cmax)was  
following a single maximum dose of  following a single 
administration. The Cmaxincreased with weekly IV dosing indicating accumulation during the 
4-week dosing period. However, there was little change in serum c oncentration on Day 29
compared with predose Day 22, indicating that steady state had been achieved after 4 weekly 
doses. T he terminal half -life of ANB019 was approximately 597 hours after SC injection and 
between  after IV injection .
2.3 Benefit/Risk Assessment
Subjects with GPP may or may not receive direct benefit from par ticipating in this study. Details 
about specific benefits and risks  for participants in this clini cal trial can be found in the 
Investigator ’s Brochure (IB) and ICF.
The safety profile of ANB019 in humans is limited.
ANB019 was well tolerated in heal thy male and female adults, an d in [ADDRESS_294358] 
in human Phase I study (Australian Study ANB019-001) when administ ered as single or multiple 
doses, up to 100 mg by [CONTACT_242684] 750 mg by [CONTACT_51215]. Overall summ aries of TEAEs by 
[CONTACT_242685] (ANB019 versus
CONFIDENTIAL Protocol ANB019-002 –Amendment 5
29 October 2019 20placebo) and no apparent dose-relat ed trends in subjects follow ing ANB019 administration.
Commonly occurring TEAEs of headache and upper respi[INVESTIGATOR_242648]. There were no death or serio us adverse events (SAEs) and 
no subjects withdrawn due to TEAEs.
There has been [ADDRESS_294359] um observations, the latter was 
not dose-related. The increase i n protozoa in the stomach has b een observed in monkeys treated 
with immune-modulating drugs ( Augey 2006 ) and is consistent with the putative mechanism of 
action of ANB019. The increased incidence of protozoa, nonforme d feces and prolapsed rectum 
were not considered adverse as they responded to veterinarian i ntervention. Gastrointestinal 
infections are clinically moni torable and, in the case of most protozoa, are readily treatable even 
in the context of immunocompromised individuals ( Farthing 2006 ). One female monkey 
receiving 60 mg/kg ANB019 IV was found moribund on Study Day 34. The cause of the 
moribund nature was not determine d and had an uncertain relatio nship to ANB019 but could be 
due to treatment-related immune -modulation. However, data publi shed on IL-[ADDRESS_294360] should be 
treated as clinically indicated.
As allergic or anaphylactic reactions may occur in subjects treat ed with mAbs, subjects should 
be observed during and after study drug administration. Subjects with true allergic/anaphylactic 
reactions should not receive further doses of the product.
As ANB019 is an mAb, based on clinical studies with other mAbs, st udy participants may 
experience symptoms of an apparent allergic reaction to the dru g, also know n as ‘cytokine 
release syndrome .’The symptoms of this vary dramatically but can include:
xMild to moderate fever, chills, headache, nausea, and vomiting.
CONFIDENTIAL Protocol ANB019-002 –Amendment 5
29 October 2019 21xModerate to severe signs and symptoms such as edema, hypotension, and pulmonary 
infiltrates (eg, blood and mucus in the lung).
Such reactions should be managed as clinically indicated and ac cording to standard clinical 
practice.
CONFIDENTIAL Protocol ANB019-002 –Amendment 5
29 October 2019 244.0 STUDY DESIGN
4.1 Overall Design
This is an open-label, single arm, multiple dose study to assess  the clinical efficacy, as well as 
the safety, tolerability, and PK of multiple doses of ANB019 in subj ects with GPP.
The screening period will be up to 42 days (6 weeks) prior to admin istration of study drug on
Day 1. Written informed consent will be obtained from each subject prior to initiating any study 
related procedures. All screening procedures will be conducted i n accordance with the Schedule 
of Activities (see Section 1.3).
On Day 1, subjects who meet the entry criteria will receive a [ADDRESS_294361] and second SC 
injections and with the Investigator ’s approval. Subjects with any ongoing AEs or SAEs at the 
time of scheduled discharge from the study center should remain  at the study center until the 
Investigator has determined that these events have resolved or ar e deemed as not clinically 
significant.
After completing Day 1 assessments, the subjects will return to t he study center for follow-up
visits on Days 3, 8, weekly from Day 8 to Day 29, and every other week up to Day 85, and 
monthly for 12 weeks to monitor changes in disease activity, saf ety, and tolerability. In addition, 
subjects will be contact[CONTACT_242686] r safety (eg, AEs and changes in 
concomitant medications) on Days 36, 50, 64, and 78.
Subjects who are nonresponders wil l be early terminated 4 weeks after the 750 mg IV dose 
administration. A nonresponder is defined as:
x“No change” on CGI: 0 points change in JDA total score and not meeting “other criteria” for 
minimally improved.
x“Worsened” based on CGI: ≥ 1-point increase in JDA total score.
Disease activity (response to study treatment) will be evaluate d using the CGI scale according to 
the modified JDA severity index, change in total BSA as measured b y modified JDA index
affected by [CONTACT_242687], systemic manifestations and laboratory finding s as per modified JDA severity 
index, GPPPGA scale, and PASI sc ore (if PP is present). In additi on, change in serum cytokines 
(including but not limited to IL-8) will be recorded. Quality of life (QoL) will be assessed using 
theDLQI.
Serum samples for PK and immunogenicity will be collected before  the administration of 
ANB019 and at the other time point s specified in the Schedule o f Activities (see Section 1.3).
Refer to Table 2 for additional information on sample collection  and time points. All subjects
CONFIDENTIAL Protocol ANB019-002 –Amendment 5
29 October 2019 25enrolled in the study will be ask ed to participate in the skin biopsy and/or genetic analysis; 
however, participation is optional and subjects will be asked to  give specific consent for these 
assessments.
Safety assessments including AE/SAE monitoring, vital signs meas urements, physical 
examination, ECGs, laboratory measurements, and urine assessmen ts will be performed during
the study.
The EOS visit will be on Day 169 and all subjects will return to t he study center for the EOS 
procedures (see Section 1.3).
4.[ADDRESS_294362] demonstrated favorable saf ety profile and prolonged 
pharmacodynamic activity in a Phase I study (ANB019-001). A loadin g dose of [ADDRESS_294363] visit on Day 169 (see Section 1.3).
The EOS is defined as the date of the last visit of the last sub ject in the study.
4.[ADDRESS_294364] will be stopped if the subjec t experiences a SAE or a clinically 
significant possibly drug related AE, which in the opi[INVESTIGATOR_1101] t he study physician, Investigator, or 
Sponsor’s medical representative, warrants discontinuation of the study for that subjec t’s 
wellbeing. Details on subject withdrawal are presented in Sectio n 7.0.
CONFIDENTIAL Protocol ANB019-002 –Amendment [ADDRESS_294365] of an authority, because of withdrawal of a positive vote by [CONTACT_242688] (IEC)/Institutional Re view Board (IRB); or if new 
safety or efficacy information leads to an unfavorable risk-bene fit judgment for any trial 
medication. The Sponsor may discontinue the trial if it becomes unjustifiable for medical or 
ethical reasons, for poor enrollmen t, or because of discontinua tion of clinical development of 
ANB0019 for safety reasons. Furthermore, the Investigator and/or  Sponsor have the right to 
close a study center, at any time, after consultation between the involved parties.
The IEC/IRB, the competent authority and the local authority must be informed within 15 days 
of a decision being made. The Investigator is obliged to inform  the local authority whereas 
information of the IEC/IRB and competent authority is to be performed b y .
If the study center has to be closed prematurely, will provide all essential documents 
necessary for the Sponsor’s Trial Master File as defined in the  Note for Guidance on G ood
Clinical Practice (GCP) (CPMP/ICH/135/95).
The study will be terminated prematurely in the following cases :
xIf SAEs occur resulting in the risk-benefit ratio not being reason able anymore.
xIf the pattern of AEs observed in the study interferes signific antly with the risk-benefit 
evaluation provided to the Investigator prior to the start of th e study.
xIf the number of discontinued subjects is so high or the number o f included subjects is so 
low that proper completion of the study could not realistically be expected.
xIf the results of parallel studies show evidence for unacceptab le risks.
xIf severe protocol violations and misconduct occur which unacce ptably affect the safety 
or rights of the subjects, or render questionable the validity o f the study results.
CONFIDENTIAL Protocol ANB019-002 –Amendment [ADDRESS_294366] s fully meet all of the inclusion c riteria and none of the exclusion 
criteria.
5.1 Inclusion Criteria
Subjects are eligible to be included in the study only if all o f the following criteria apply:
1. Male and female subjects must be [ADDRESS_294367] a Japanese Dermatology Association severity index total s core of >[ADDRESS_294368] 10% of BSA or
have a GPPPGA score of at least moderate severity.
4. Must be candidates for systemic therapy or phototherapy as asse ssed by [CONTACT_3786].
5. Meet the following laboratory screening criteria:
a) Hemoglobin ≥90 g/L (≥9g / d L )
b) White blood cell count ≥3.0 × 109/L(≥3.0 ×1 03/μL)
c)Platelets ≥ 100 × 109/L(≥100 ×1 03/μL)
d) Serum creatinine <132.6 μmol/L (<1.5 mg/dL)
e) Alanine aminotransferase (ALT) and aspartate aminotransferase  (AST) levels 
≤1.5× upper limit of normal (ULN)
f) Total b ilirubin ≤ 1.5 × ULN. Subjects with known Gilbert’s di sease who have a
serum bilirubin <3 × ULN may be enrolled
6. Body mass index (BMI) of 18 to 36 kg/m2, inclusive, {BMI = weight (kg)/ [height 
(m)]2}, and total body weight >50 kg (110 lb).
7. Subjects must be otherwise in a  good health as judged by [CONTACT_941] I nvestigator based on 
medical history, physical examination, ECG, hematology, and chem istry laboratory 
parameters, and urinalysis.
8. Contraceptive use by [CONTACT_242689] l ocal regulations 
regarding the methods of contraception for those participating in clinical studies.
Contraception and pregnancy:
x A male subject must agree to use contraception as detailed in Appendix [ADDRESS_294369] 2 20 days (which 
includes the duration of relevant exposure plus the duration of  sperm cycle) after 
the study treatment and refrain from donating sperm during this period.
x Female subjects:
CONFIDENTIAL Protocol ANB019-002 –Amendment [ADDRESS_294370] (beta-human chorionic gonadotropin) at Screening and a nega tive urine 
pregnancy test at baseline (see Appendix 6 ), is not breastfeeding, and at least 1 of
the following conditions apply:
i) Not a woman of childbearing potential (WOCBP) as defined in Appendix 6 .
OR
ii) A WOCBP who agrees to follow the contraceptive guidance in Appendix [ADDRESS_294371]’s selected form of contraception must be effective by t he time the female 
subject enters into the study (eg, hormonal contraception shoul d be initiated at least 
28 days before Day 1).
9. Capable of giving signed informed consent as described in Appendix [ADDRESS_294372] ed in the ICF and in this 
protocol.
5.2 Exclusion Criteria
Subjects are excluded from participating in the study if any of  the following apply:
1. Have other forms of psoriasis (eg, guttate) except PP.
2. Have concomitant dermatolog ical (eg, subcorneal pustular derm atosis, impetigo 
herpetiformis, acute generalized exanthematous pustulosis) or me dical conditions 
which may interfere with the Investigator ’s ability to evaluate the subject’s response to 
therapy.
3. Have a history of clinically significant (as determined by [CONTACT_16032]) cardiac, 
pulmonary, neurologic, gastrointestinal, endocrine, hematologic al, renal, hepatic, 
cerebral or psychiatric disease, or other major uncontrolled di sease (a poorly 
controlled medical condition, such as but not limited to, poorl y controlled diabetes, 
unstable ischemic heart dise ase, uncontrolled hypertension (systolic ≥ 160 mmHg
and/or diastolic ≥ 95 mmHg based on the average of 2 blood tension measurements),
and moderate to severe heart failure [[LOCATION_001] Heart Association  Class III/IV]).
4. History of chronic or recurrent infectious disease, including  but not limited to chest 
infection (eg, sinusitis, bronchitis, and bronchiectasis), urin ary tract infection (eg, 
recurrent pyelonephritis), and skin infection (eg, abscesses, i nfected skin wounds, or
ulcers) within 24 months prior to Screening.
5. History of a serious infection (eg, hepatitis, pneumonia) tha t led to hospi[INVESTIGATOR_242649] 3 months 
prior to Screening or any recent infection requiring systemic an tibiotic or systemic 
antiviral treatment within 4 weeks of baseline.
6. History or any evidence of active infection within 4 weeks of b aseline (eg,
bronchopulmonary, urinary, or gastrointestinal).
CONFIDENTIAL Protocol ANB019-002 –Amendment [ADDRESS_294373] to develop infection, eg,
rectal fissures, poor dentition.
8. History of an opportunistic infection (eg, Pneumocystis carinii , aspergillosis, or
mycobacteria other than tuberculosis [TB]), parasitic infection s, including, but not 
limited to,, helminths, protozoa, Trypanosoma cruzi within 6 months of screening.
9. History of a herpes zoster infection within 2 months prior to screening.
10. Known or suspected autoimmune disorder, including but not li mited to rheumatoid 
arthritis, fibromyalgia, systemic lupus erythematosus, polymyal gia rheumatica, giant 
cell arteritis, Bech et’s disease, dermatomyositis, multiple sclerosis, moderate to severe 
asthma, or other severe forms of a topy, any autoimmune vasculiti s, autoimmune 
hepatitis, or any other active autoimmune disease for which a s ubject requires medical 
follow-up or medical treatment.
11. Any history of known or suspec ted congenital or acquired imm unodeficiency state or 
condition that would compromise the subject’s immune statu s (eg, history of 
splenectomy).
12. Any major surgery within 4 weeks of study drug administration .
13. Malignancy or history of malignancy within 5 years, except for  treated basal cell or 
squamous cell in situ carcinomas of the skin or squamous cell carc inomas deemed by 
[CONTACT_242690].
14.History of any significant drug allergy or reaction (such as an aphylaxis or 
hepatotoxicity) and reactivity to , a c omponent of ANB019 formulation, 
or the inactive ingredients (excipi[INVESTIGATOR_840]) .
a) Have taken the following dru gs within the specified period pri or to Screening or
Baseline:Topi[INVESTIGATOR_73201] (in cluding corticosteroid, retinoid s or vitamin A or D
analog preparations, tacrolimus, calcineurin inhibitor, topi[INVESTIGATOR_2855]  H1 and H2 
antihistamines, tar preparations, topi[INVESTIGATOR_166464], other  medicated topi[INVESTIGATOR_113899]) or herbal preparation within 2 weeks prior to baseline.
b) Systemic therapy including but not limited to cyclosporine, m ethotrexate, 
acitretin, alitretinoin, fumaric acid esters, corticosteroids or  any other 
immunosuppressant or immunomodulation drugs within 4 weeks prior  to baseline. A
tapering washout of systemic therapi[INVESTIGATOR_014] (eg, cyclosporine, methot rexate, and retinoids) 
can be used and the study drug can be introduced before the end of the washout 
period.
c) Phototherapy ie, ultraviolet light B and photochemotherapy (eg , psoralen and 
ultraviolet A [PUVA]) within 4 weeks prior to baseline.d) Previous treatment with anti- tumor necrosis factor/interleuki n (IL-12/IL-23) and 
IL-[ADDRESS_294374] prior to basel ine.
e) Live attenuated vaccine within 12 weeks of screening and during  the study.
f) Any investigational drug within 4 weeks or 5 half-lives, which ever is longer, of
screening.
CONFIDENTIAL Protocol ANB019-002 –Amendment 5
29 October 2019 30g) Antibiotic or antiviral medica tion within 4 weeks of baseline.
15. Topi[INVESTIGATOR_242650] (without pharmacological active ingre dients) for pustular 
psoriasis are allowed during the study, except within 24 hours p rior to the study visits. 
Rescue medication will be directe d by [CONTACT_242691] . (Refer Section
6.5.1 ).
16. History of active TB or latent TB infection as indicated by a pos itive 
QuantiFERON®-TB Gold test at Screening or within 6 months prior to Day 1 (If th e 
test is indeterminate, it can be repeated only once), chest x-r ay, and/or clinical 
examination or has had active TB disease at any time in the pas t.
17. History of drug, alcohol, or other substance abuse, or other factors (eg, excessive 
caffeine use) limiting the ability to cooperate and to comply w ith the study protocol, as 
determined by [CONTACT_737].
18. Pregnant or lactating females, or females who intend to becom e pregnant during the 
study period.
19. Donation of blood to a blood bank or in a clinical study (ex cept at the Screening Visit)
within 4 weeks of study drug administration (within 2 weeks for p lasma only).
20. Blood transfusion within [ADDRESS_294375] x-ray at Screeni ng or within 6 months prior 
to Screening.
24. Clinically significant abnormalities on 12-lead ECG at Scree ning.
25. Evidence of clinically significant abnormality in urinalysis  as determined by [CONTACT_3786].
26. Positive blood screen for hepatitis C antibody, hepatitis B surface antigen, or HIV-1 or 
HIV-2 antibodies.
5.3 Lifestyle Considerations
Exposure to sunlight should be avoided during the study.
5.4 Screen Failures
Screen failures are defined as subjects who consent to participa te in the clinical study but are not 
subsequently enrolled in the study. A minimal set of screen failu re information is required to 
ensure transparent reporting of screen failure subjects to meet  the Consolidated Standards of 
Reporting Trials publishing re quirements and to respond to queri es from regulatory authorities. 
Minimal information includes demography, screen failure details,  eligibility criteria, and any 
SAE.
CONFIDENTIAL Protocol ANB019-002 –Amendment 5
29 October 2019 31Individuals who do not meet the criteria for participation in t his study (screen failure) may be 
rescreened once after discussion with Medical Monitor. Rescreened  subjects should not be 
assigned the same subject number as for the initial screening.
CONFIDENTIAL Protocol ANB019-002 –Amendment 5
29 October 2019 326.0 STUDY TREATMENT
Study treatment is defined as any investigational treatment(s), marketed product(s), placebo, or
medical device(s) intended to be administered to a subject accord ing to the study protocol.
6.1 Study Treatment Administered
Eligible subjects will receive 750 mg of ANB019 IV in an open-lab el manner followed by 
3 doses of 100 mg SC administered on Days 29, 57, and 85.
Due to the potential for infusion reactions with protein drugs, ANB019 should be administered in 
an environment under close s upervision of a physician and where  full resuscitation facilities are 
immediately available. Allergic/anaphylactic reactions and infu sion-related reactions typi[INVESTIGATOR_242651], or within several hours of dose administration. T he onset of symptoms may be 
rapid, and some reactions may be life-threatening. The study tre atment should be immediately 
stopped and permanently withdraw n in case of severe allergic/ana phylactic reactions. For 
treatment of allergic reactions, current local standard of care  guidelines should be followed.
Study treatment details are provided in Table 1 .
CONFIDENTIAL Protocol ANB019-002 –Amendment 5
29 October 2019 33Table 1 Study Treatment Details
Study Treatment Name: [CONTACT_242734]019
(anti-interleukin-36 receptor [IL-36R] monoclonal antibody)
Dosage Formulation: The drug product i sformulated as 
Study Treatment Description ANB019 drug product is a sterile, clear to slightly opalescent and 
colorless to yellow solution supplied in a single -use, 2R, Type I 
glass vial with a 
Unit Dose Strength(s)/Dosage Level(s): A dose of 750 mg/ intravenously ( IV)followed by 3 doses 
of 100 mg/mL subcutaneously ( SC)administered on Days 29, 57, 
and 85.
Route of Administration IV infusion (1 dose) and SC injections (3 doses).
Dosing Instructions: ANB019 will be administered to subjects by [CONTACT_242692] a t otal 
volume of  with sterile normal saline (0.9% NaCl) .
Infusions will be administered over .The infusion may be 
slowed or interrupted for subjects experiencing infusion -related 
AEs.
For SC injections, ANB019 should be prepared by [CONTACT_242693] g a 
dosing needle. No furt her dilution is required. Subjec ts receiving 
ANB019 will receive (100 mg) SC injection. The injections 
should be rotated with each dose and should not be given into 
moles, scars, tattoos or areas wh ere the skin is tender, bruise d, red, 
hard, or not intact. Abdominal administration is the preferred site 
for SC doses.
6.2 Preparation/Handling/Storage/Accountability
1. The Investigator or designee mu st confirm appropriate temperatu re conditions have 
been maintained during transit for all study treatment received and any discrepancies 
are reported and resolved before use of the study treatment.
2. Only subjects enrolled in the study may receive study treatme nt and only authorized 
study center staff may supply or administer study treatment. All study treatments must 
be stored in a secure, environmen tally controlled, and monitored (manual or 
automated) area in accordance with the labeled storage condition s with access limited 
to the Investigator and authorized study center staff.
3.ANB019 vials must be refrigerated at 2°C to 8°C (36°F to 46°F) until the day of use. 
ANB0 [ADDRESS_294376] or expi[INVESTIGATOR_242652]. Vial contents should not be frozen or shaken. ANB 019 vials may be 
stored at room temperature (8°C to 25°C [46°F to 77°F]) in a diluted or undiluted state 
for up to amaximum of . Once ANB019 has been di luted with sterile 0.9% 
NaCl, the solution may be stored at room temperature (8°C to 25 °C [46°F to 77°F]) for 
CONFIDENTIAL Protocol ANB019-002 –Amendment 5
29 October 2019 34upto . Vials are intended for single -use only; therefore, any remaining solution 
should be disc arded.
4. The Investigator, institution, or the head of the medical ins titution (where applicable) 
is responsible for study treatment accountability, reconciliati on, and record 
maintenance (ie, receipt, reconciliation, and final disposition r ecords).
5. Further guidance and information for the final disposition of unused study treatment 
are provided in the  Pharmacy Manual .
The Investigator, a member of the study center staff, or a hospi [INVESTIGATOR_242653]. These forms must be available for inspection at any time.
6.3 Measures to Minimize Bias: Randomization and Blinding
This section is not applicable as this is an open-label study.
6.[ADDRESS_294377] be recorded in the el ectronic case report forms 
(eCRFs). Infusion start date/ti me and infusion end date/time wil l be documented in the subject ’s
eCRF. Any infusion interruptions (stop date/time and restart da te/time), changes in infusion rate,
and/or incomplete dose administ ration will also be documented in  the subject ’seCRF.
6.5 Concomitant Therapy
Any medication or vaccine (including over-the-counter or prescr iption medicines, vitamins,
and/or herbal supplements) that the subject is receiving at the time of enrollment and receives 
during the study must be recorded on the eCRF along with:
xReason for use.
xDates of administration inc luding start and end dates.
xDosage information including dose and frequency.
In addition, all prior medications used to treat GPP disease co nditions and any other medications 
taken within [ADDRESS_294378] 4 weeks before study treatment adminis tration. Dose adjustments of 
these treatments should be avoided during the study.
The Medical Monitor should be contact[CONTACT_163545].
Treatment with bland emollients (without pharmacological active ingredients) will be permitted 
throughout the trial, except within 24 hours prior to the study v isits.
CONFIDENTIAL Protocol ANB019-002 –Amendment [ADDRESS_294379] of excluded medications/therapy is provided in Appendix 5 .
6.5.1 Rescue Medicine
Rescue medication will be directed by [CONTACT_242691] . Rescue medication in the form 
of topi[INVESTIGATOR_11930] (eg, b etamethasone valerate ointment and cream, mometasone furoate 
ointment and cream) can be used during the study for a period o f up to [ADDRESS_294380] 1 month following the 
administration of study treatment. Rescue medication may be use d at the Investigator’s 
discretion only if medically indicated for the wellbeing of the  subject. The date and time of
rescue medication administrati on as well as the name [CONTACT_242735].
The addition of any systemic psoriasis medication that is likel y to impact psoriasis signs and 
symptoms (eg, cyclosporine, methotrexate, and retinoid) will re quire the subject to be withdrawn 
from the study.
6.6 Dose Modification
No dose modification is allowed in this study. Study treatment c an be interrupted temporarily 
only once or permanently if deemed necessary as per the Investi gator ’s discretion. Refer to 
Section 7.1.
6.7 Treatment After the End of the Study
All subjec ts will return to th e study center for the EOS (Day 169) or ET visit for final safety and 
EOS asses sments. After this visit, subjec ts should be treated accordi ng to the Investigator’s 
clinical judgment. Care after EOS/ET will not be provided by [CONTACT_242694].Any significant 
AE which in the opi[INVESTIGATOR_2511] I nvestigator is related to the study drug , SAE, o r pregnancy 
occurring through the EOS visit and should be reported to the  Safety team (see 
Appendix 4)and followed -up until outcome.
CONFIDENTIAL Protocol ANB019-002 –Amendment [ADDRESS_294381] DISCONTINUATION/WITHDRAWAL
7.1 Discontinuation of Study Treatment
Discontinuation from study treat ment will require subjects to di scontinue from the study. Study 
treatment may be interrupted only once during the study for an AE at the Investigator’s 
discretion.
7.1.1 Temporary Interruption
Only one dose of study treatment may be interrupted temporarily in the case of an AE per the 
Investigator ’s discretion. The Medical Monitor and the Sponsor should be informed of all deta ils 
pertaining to the decision. Study drug may be resumed at the next  scheduled dosing visit after 
discussion with the Medical Monitor. In the case of a recurring o r new AE after study treatment 
has resumed, the subject will be early terminated. If a clinical ly significant finding is identified 
(including, but not limited to cha nges from baseline) after enr ollment, the Investigator or 
qualified designee will determine  if any change in subject mana gement is needed. Any new 
clinically relevant finding will be reported as an AE.
7.1.[ADDRESS_294382] Discontinuation/Withdrawal from the Study
A subject may withdraw from the study at any time at his/her own request, or may be withdrawn 
at any time at the discretion of the Investigator for safety, be havioral, compliance, or
administrative reasons.
In case of early withdrawal from the study drug and study, the s ubject will be required to attend 
the ET visit (see the Schedule of Activities in Section 1.3).Subjects must be withdrawn from the 
study under the following circumstances, any significant AE which  in the opi[INVESTIGATOR_242654], or pregnancy occ urring through the EOS visit 
and should be followed-up until outcome:
xPrior to study treatment administration, the Investigator decides that the subject should be 
withdrawn or is at risk. If this decision is made because of an AE or a clinically signi ficant 
laboratory value, the study drug should not be administered and appropriate measures are to 
be taken . AnaptysBio Inc. and/or is to be notified immediately.
xSignificant deviation/lack of compliance with protocol other tha n the use of 
excluded/prohibited medications.
xUse of any excluded/prohibited medications that in the opi[INVESTIGATOR_242655] ( Appendix 5 ).
xTermination of the study by [CONTACT_9304].
xPregnancy ( Appendix 6 and Section 8.3.5 Pregnancy).
CONFIDENTIAL Protocol ANB019-002 –Amendment 5
29 October 2019 37xNew information suggests taking part in the study may not be in  the participant’s best 
interest.
If the subject withdraws consent for disclosure of future informa tion, the Sponsor may retain and 
continue to use any data collec ted before such a withdrawal of consent.
If a subject withdraws from the study, he/she may request destru ction of any samples taken and 
not tested, and the Investigator must document this in the study center study records.
See Schedule of Activities (Section 1.3) for data to be collected  at the time of study 
discontinuation and follow-up and fo r any further evaluations t hat need to be completed.
Subjects withdrawing from the study prematurely for reasons oth er than a study drug related AE 
may be replaced at the discretion of the Investigator and Spons or to ensure the required number 
of evaluable subjects.
7.[ADDRESS_294383] fails to return t o the clinic for a required study 
visit:
xThe study center must attempt to contact [CONTACT_242695] s ubject on the importance of maintai ning the assigned visit 
schedule and ascertain whether or not the subject wishes to and/ or should continue in the 
study.
xBefore a subject is deemed lost to follow-up, the Investigator or designee must make every 
effort to regain contact [CONTACT_1155] (where possible, [ADDRESS_294384] ’s last known mailing address or local equivalent methods). 
These contact [CONTACT_9300] ’s medical record .
xShould the subject continue to be  unreachable, he/she will be co nsidered to have withdrawn 
from the study.
CONFIDENTIAL Protocol ANB019-002 –Amendment [ADDRESS_294385] should 
continue or discontinue in the study.
xAdherence to the study design requirements, including those spe cified in the Schedule of 
Activities (see Section 1.3), is essential and required for study conduct.
xAll screening evaluations must be completed and reviewed to confi rm that potential subjects
meet all eligibility criteria. The Investigator will maintain a s creening log to record details of 
all subjects screened and to confirm eligibility or record reas ons for screening failure, as 
applicable.
xProcedures conducted as part of the subject ’s routine clinical management ( eg, blood count) 
and obtained before signing of the I CF may be utilized for scre ening or baseline purposes 
provided the procedures met the protocol specified criteria and  were performed within the
time frame defined in the Sche dule of Activities (see Section 1.3).
xThe maximum amount of blood collected from each subject over the  duration of the study, 
including any extra assessments that may be required, will not e xceed 204 mL. Repeat or 
unscheduled samples may be taken for safety reasons or for tech nical issues with the 
samples.
8.1 Efficacy Assessments
It is recommended that the same In vestigator/Sub-Investigator co mplete the scales and 
questionnaires at all time points for a given subject.
8.1.1 Clinical Global Impression
The CGI scale will be used to assess the clinical response to s tudy treatment. The change will be 
categorized as “Very much improved, ”“Much improved, ”“Minimally improved, ”“No change, ”
and “Worsened ”according to the modified JDA sev erity index total score (see Appendix 8 ).
8.1.2 Modified Japanese Dermatology Association (JDA) Severity In dex
The modified JDA severity index score will be used for the assessme nt of the skin lesions, 
assessment of systemic manifestations and laboratory findings, and change in affected BSA of
erythema, pustules, and edema (see Appendix 9 ).
The total severity score is categorized as Mild (total score: 1 t o 6), Moderate (total score: 7 to 
10), or Severe (total score: 11 to 17).
CONFIDENTIAL Protocol ANB019-002 –Amendment 5
29 October 2019 398.1.3 Psoriasis Area Severity Index (Only in Subjects With PP)
Psoriasis Area Severity Index scores will be used to determine the treatment response in subjects 
with PP. The PASI total score includes plaque characteristics (i e, erythema, induration, scaling), 
percentage of BSA affected and s hould be calculated by [CONTACT_242696] (EDC) (see
Appendix 10 ).
8.1.4 Generalized Pustular Psoriasis Physician’s Global Assessment Scale
The GPPPGA is a physician-based assessment of the severity of GP P (specifically pustules, 
erythema, and scaling or crusting of pustular psoriasis lesions ). Each component is scored on a 5-
point scale, ranging from 0 (lea st severe) to 4 (most severe) t o assess the severity of GPP
(Bachelez 2019; Marrakchi 2019 ). The average is calculated for scoring.
Subjects will be assessed using the GPPPGA at each study visit (excluding those visits that are 
phone calls). Refer to Appendix [ADDRESS_294386]’s QoL. The 
aim of this questionnaire is to measure how much the skin condi tion has affected subject’s life 
during the previous week.
Subjects will be asked to recall their experiences during the prev ious week by [CONTACT_20230] 
[ADDRESS_294387] who is 
asked to fill it in without the need for a detailed explanation (seeAppendix 12 ).
8.2 Safety Assessments
Planned time points for all safety assessments are provided in t he Schedule of Activities (see
Section 1.3).
8.2.1 Physical Examinations
Complete physical examinations  will be performed at the time poi nts indicated in the Schedule 
of Activities (see Section 1.3).
xA complete physical examination will include assessments of gener al appearance; skin; 
head/neck; pulmonary, cardiovascul ar, gastrointestinal, external  genitourinary, lymphatic, 
and musculoskeletal system; extremities; eyes (inspection and v ision control); nose; throat; 
and neurologic status.
xA detailed examination of the ski n should be performed at the t ime points indicated in the 
Schedule of Activities for the e fficacy assessments (eg, CGI, m odified JDA severity index, 
PASI [if PP is present]).
Investigators should pay special attention to clinical signs re lated to previous serious illnesses.
CONFIDENTIAL Protocol ANB019-002 –Amendment [ADDRESS_294388] x-ray o r as indicated by [CONTACT_242697] 6 months prior to 
screening and other time points specified in the Schedule of Ac tivities (see Section 1.3).
8.2.3 Height and Weight
Height will be measured only at the Screening Visit. Weight wil l be measured at the Screening 
and EOS Visits.
8.2.4 Vital Signs
xBody temperature, pulse rate, blood pressure, and respi[INVESTIGATOR_696] r ate will be assessed at the time 
points specified in Schedule of Activities (see Section 1.3).
xBlood pressure and pulse measurements will be assessed in the s upi[INVESTIGATOR_103645] a 
completely automated device. Ma nual techniques will be used onl y if an automated device is 
not available.
xBlood pressure and pulse measurements should be preceded by [CONTACT_207596] [ADDRESS_294389] in a quiet setting without distractions (eg , television, cell phones).
xVital signs including body temperature, respi[INVESTIGATOR_697], and pul se rate (after [ADDRESS_294390]) should be measured once. Arterial blood pressure should b e measured twice (at intervals 
of approximately 5 minutes), using a validated device. Average of b oth the readings will be 
entered in eCRF.
8.2.5 Electrocardiograms
xA single 12-lead ECG will be obtained at the time points specifie d in Schedule of Activities 
(see Section 1.3) using a validated ECG machine that automatically calculates the  pulse rate 
and measures PR, QRS, QT, and QTcF intervals.
xThe ECG will be reviewed by [CONTACT_242698]. 
Instructions and guidelines for collection (e.g, equipment), tr ansmission, and archiving of 
ECG data will be provided in the ECG Manual.
xThe ECG will be reviewed by [CONTACT_242699].
xThe ECG individual data (with the exception of clinical signifi cance) does not need to be 
entered into EDC.
8.2.6 Photography
Photography of the lesions will be performed at the time points mentioned in Schedule of 
Activities (see Section 1.3) for documentation purpose only. A standardized approach to
collection of photographs will be de scribed in the manual provi ded to sites. Photographs will be 
CONFIDENTIAL Protocol ANB019-002 –Amendment [ADDRESS_294391] of clinical laboratory tests to be performed and t o the Schedule of 
Activities (see Section 1.3) for the timing and frequency of the tests.
xA central laboratory will be used to perform all laboratory tes ts except urine pregnancy 
dipstick which will be assessed by [CONTACT_216580]. However, local  laboratory tests will be 
allowed in the event that the cen tral laboratory results will n ot be available immediately and 
the Investigator needs to take a n immediate decision for any safe ty concerns based on 
laboratory results.
xThe Investigator must review the laboratory report, document thi s review, and record any 
clinically relevant changes occurring during the study in the A E section of the case report 
form. The laboratory reports must be filed with the source docu ments. Clinically significant 
abnormal laboratory findings are those that are not associated with the underlying disease, 
unless judged by [CONTACT_242700]’s condition.
xAll laboratory tests with values considered clinically signific antly abnormal during 
participation in the study including the subject’s last EOS visit should be repeated until 
the values return to normal or baseline or are no longer conside red clinically significant 
or judged medically stabilized by [CONTACT_242701].
If such values do not return to normal/baseline within a period of time judged 
reasonable by [CONTACT_737], the etiology should be identifi ed and the Sponsor
notified.
All protocol-required laboratory assessments, as defined in Appendix [ADDRESS_294392] be 
conducted in accordance with the Laboratory Manual and the Sched ule of Activities 
(see Section 1.3).
If laboratory values from non-prot ocol specified laboratory ass essments performed at 
the institution’s local laboratory require a change in subject management or are 
considered clinically significant by [CONTACT_737] (eg, SAE o r AE or dose 
modification), then the results  must be recorded in the eCRF.
8.2.[ADDRESS_294393]
At Days 36, 50, 64 and 78, subjects will be contact[CONTACT_3012] t o assess for safety. Study staff 
will review for any new AEs or changes in concomitant medication s. Any new/changed AEs and 
concomitant medications will be recorded on the eCRF.
8.3 Adverse Events
The definitions of an AE and SAE can be found in Appendix 4 .
CONFIDENTIAL Protocol ANB019-002 –Amendment [ADDRESS_294394] (or, when appropr iate, by a caregiver, surrogate, 
or the participant's legally authorized representative).
The Investigator and any designees are responsible for detecting , documenting, and recording 
events that meet the defin ition of an AE or SAE and remain resp onsible for following up AEs,
including that are serious, considered related to the study tre atment or study procedures, or that 
caused the subject to discontinue the study (see Section 7.0).
8.3.1 Time Period and Frequency f or Collecting AE and SAE Inform ation
All SAEs will be collected from the signing of the ICF until the EOS visit at the time points 
specified in the Schedule of Activities (see Section 1.3).
All SAEs will be recorded and reported to the Sponsor or designee within [ADDRESS_294395] has been discharged from t he study, and he/she consider s the event to be reasonably 
related to the study treatment or study participation, the Inve stigator must promptly notify the
 Safety .
8.3.2 Method of Detecting AEs and SAEs
The method of recording, evaluating, and assessing causality of  AE and SAE and the procedures 
for completing and transmitting SAE reports are provided in Appendix 4 .
Care will be taken not to introduce bias when detecting AEs and /or SAEs. Open-ended and 
non-leading verbal questioning of the subject is the preferred m ethod to inquire about 
AE occurrences.
8.3.3 Follow-up of AEs and SAEs
After the initial AE/SAE report, the Investigator is required to proactively follow each subject at 
subsequent visits/contacts. All SAEs, and non-serious AEs of spe cial interest (as defined in 
Section 8.3.6 ), will be followed until resolution, stabilization, the event i s otherwise explained, 
or the subject is lost to follo w-up (as defined in Section 7.3). Further information on follow-up
procedures is given in Appendix [ADDRESS_294396] s and the 
safety of a study treatment under clinical investigation are met.
CONFIDENTIAL Protocol ANB019-002 –Amendment 5
29 October 2019 43xThe  Safety has a legal responsibility to notify both the local regulatory 
authority and other regulatory agencies about the safety of a s tudy treatment under clinical 
investigation. The  Safety will comply with country specific regulatory 
requirements relating to safety reporting to the regulatory authority, IRB/IEC, and 
Investigator s.
xInvestigator safety reports must be prepared for suspected unexpected s erious adverse 
reactions according to local regulatory requirements and  Safety policy and 
forwarded to Investigator s as necessary .
xAnInvestigator who receives an Investigator safety report describing an SAE or other 
specific safety information ( eg, summary or listing of SAEs) from the 
Safety will review and then file it along with the IBand will notify the IRB/IEC, if
appropriate according to local requirements.
8.3.[ADDRESS_294397] 28 days after the las t dose.
xIf a pregnancy is reported, the Investigator should inform the  Safety within 
24hours of learning of the pre gnancy and should follow the procedures outlined in
Appendix 6 .
xIf a pregnancy occurs, it will be followed-up to determine the ou tcome, but no longer than 
6 to 8 weeks after the estimated delivery date.
xAbnormal pregnancy outcomes (eg, spontaneous abortion, fetal de ath, stillbirth, congenital 
anomalies, and ectopic pregnancy) are considered SAEs.
8.3.[ADDRESS_294398]
The following events are considered AESI in this study.
xSerious infection (requiring hospi[INVESTIGATOR_059]; or with fatal outc ome or sepsis; or requiring IV 
antibiotics/antimicrobials).
xSerious allergic reaction.
xGastrointestinal clinical manifestations including infections.
All AESI, including follow-up, should be reported in an expedite d manner. (Please follow 
procedures for AE/SAE recording and reporting outlined in Appendix 4 ).
8.3.[ADDRESS_294399] t he study center after completing 
CONFIDENTIAL Protocol ANB019-002 –Amendment [ADDRESS_294400] and second SC injections and with the Investiga tor’s approval.
8.3.8 Disease-related Events and/or Disease-related Outcomes Not  Qualifying as 
AEs or SAEs
The following disease-related events (DREs) are common in subje cts with GPP and can be 
serious/life-threatening:
xFlare of GPP.
Because these events are typi[INVESTIGATOR_103659], they will not be 
reported according to the standa rd process for expedited report ing of SAEs even though the 
event may meet the definition of a  SAE. These events will be re corded on the corresponding 
eCRF page in the subject ’s eCRF.
NOTE: If either of the following conditions applies, then the event must be recorded and 
reported as an SAE (instead of a DRE):
The event is, in the Investigator ’s opi[INVESTIGATOR_1649], of greater intensity, frequency , or duration than 
expected for the individual subject.
OR
The Investigator considers that there is a reasonabl e possibility that the event was related to 
study treatment.
8.4 Treatment of Overdose
For this study, any dose of ANB019 >750mg/ within a 24-hour time period onDay 1
and >100mg o n Day s29, 57, and 85 will be considered an overdose.
In the improbable event of a suspected overdose, the following procedures should be executed:
xAdministration is to be discontinued.
xThe subject is to be monitored clinically.
xSupportive measures are to be undertaken as clinically indicate d.
xElectrocardiography and clinical laboratory evaluations (ie, bl ood glucose, hepatic enzymes, 
creatinine, blood urea nitrogen, cr eatine kinase, and complete blood count) are to be 
performed and followed until all values return to baseline leve ls and AEs subside.
Sponsor does not recommend specific treatment for an overdose.
In the event of an overdose, the Investigator should:
1. Contact [CONTACT_27465].
2. Closely monitor the subject for any AE/SAE and laboratory abnor malities and follow-
up until resolution.
CONFIDENTIAL Protocol ANB019-002 –Amendment [ADDRESS_294401] dose 
of study treatment if requested by [CONTACT_1689] (determin ed on a case-by-case 
basis).
4. Document the quantity of the excess dose as well as the durat ion of the overdose in the 
eCRF.
Decisions regarding dose interruptions or modifications will be  made by [CONTACT_242702].
8.[ADDRESS_294402] for PK assessment s during the study. Each serum 
sample will be divided into 2 ali quots (1 each for primary and a back-up). Samples collected for 
analyses of ANB019 serum concentration may also be used to corre late exposure to safety or 
efficacy aspects related to concerns arising during or after th e study.
The actual date and time (24-hour clock) of the blood sample coll ection will be recorded in the 
subject ’s eCRF. The details of blood sampl e collection, sample t ube labeling, sample 
preparation, storage, and shippi [INVESTIGATOR_242656] a separate Laboratory Manual.
The measurement of the concentrations of ANB019 will be performed  using a validated assay 
method. The analytical methods used to measure concentrations o f ANB019 will be described in 
a separate bioanalytical report. Only samples which are within t he stability window of the 
bioanalytical assay will be analyzed.
CONFIDENTIAL Protocol ANB019-002 –Amendment 5
29 October 2019 46Table 2 PK/ADA Sample Collection and Timepoints
Study VisitPK Sample Timepoint
PlasmaADA Sample Timepoint
Serum
Day 1aPredose Predose
1 hr (r10 min) postdose
4 hrs (r10 min) post-dose
Day 3 Anytime
Day 8 Anytime
Day 15 Anytime 
Day 22 Anytime
Day 29 Predose Predose
Day 43 Anytime
Day 57 Predose Predose
Day 71 Anytime
Day 85 Predose Predose
Day 113 Anytime
Day 141 Anytime
Day 169 Anytime Anytime
ADA = anti-drug antibodies; hr(s) = hour(s); min = minutes; PK = phar macokinetic.
aInfusion of study treatment will take approximately [ADDRESS_294403] occur exactly 3 hours after the 1-hour 
collection is completed.
8.6 Pharmacodynamics
Pharmacodynamic parameters will not be evaluated in this study.
8.7 Genetics
Pharmacogenomic testing is optional and voluntary. For those pat ients who signed the original 
pharmacogenomics ICF, a whole blood s ample will be collected at t he study visit as specified in 
the study flow chart and this sample will be stored for future analysis. Specific procedures for 
storage and shippi[INVESTIGATOR_242657] d in a lab manual.
DNA testing will be performed only at Day 1. Ribonucleic acid (RNA) testing will be performed 
on Day [ADDRESS_294404] DNA and RNA from the samples (See Appendix 7 for information 
regarding genetic research). Details on processes for collectio n and shipment and destruction of
these samples can be found in a separate Laboratory Manual.
8.8 Biomarkers
Samples will be collected accordi ng to the schedule presented i n Section 1.3to measure skin 
biopsy biomarkers. Measurements may include but are not limited to immunohistochemistry and
Reverse Transcription Polymeras e Chain Reaction to assess psoria sis associated markers of 
CONFIDENTIAL Protocol ANB019-002 –Amendment 5
29 October 2019 47inflammation (eg, IL-17, IL-23, IL-8, dendritic cells, epi[INVESTIGATOR_242658], and leukocytes 
infiltration).
The actual date and time of the s ample collection will be record ed in the subject ’s eCRF. The 
details of blood sample collection, sample tube labeling, sampl e preparation, storage, and 
shippi[INVESTIGATOR_242659] a separate Laboratory Manual.
The measurement of skin biopsy biomarkers may be performed by [CONTACT_242703] (eg, a 
university Investigator) designated by [CONTACT_1034].
Samples may be stored for a maximum of 5 years (or according to l ocal regulations) following 
the last subject ’s last visit for the study at a facility selected by [CONTACT_242704].
A 5 mL blood sample will be collected in a serum separator tube to  measure change in serum 
cytokine (including but not limit ed to IL-8) concentration at eac h time point mentioned in the 
Schedule of Activities (see Section 1.3). A qualified fit for purpose assay will performed by [CONTACT_242705].
8.9 Immunogenicity Assessments
Antibodies to ANB019 will be evalu ated in serum samples collected from all subjects according 
to the Schedule of Activities (see Section 1.3) and Table 2. Additionally, serum samples should 
also be collected at the EOS visit from subjects who discontinue d study treatment or were 
withdrawn from the study. Each s erum sample will be divided int o 2 aliquots (1 each for primary 
and a back-up).
The ADA analysis will be conducted using a screening assay agai nst ANB019 to identify 
potential positive ADA samples. Samples testing positive for AD A in the screening assay will be 
further evaluated in a confirmatory assay against ANB019 to con firm the positive status of 
samples scored potentially positive by [CONTACT_242706]. In confirmed positive samples, a third 
assay will be performed to deter mine the titer of confirmed pos itive samples. Confirmed positive 
ADA samples may be fur ther evaluated for neutralizing activity.
The detection and characterizati on of antibodies to ANB019 will b e performed using a validated 
assay method by [CONTACT_23788]. All sam ples collected for detection of 
antibodies to study treatment will also be evaluated for ANB019 s erum concentration to enable 
interpretation of the antibody data . Only samples within the sta bility window of the assay will be 
analyzed.
8.10 Health Economics or Medical Resource Utilization and Health E conomics
Health Economics/Medical Resource Utilization and Health Economi cs parameters will not be
evaluated in this study.
CONFIDENTIAL Protocol ANB019-002 –Amendment 5
29 October 2019 489.0 STATISTICAL CONSIDERATIONS
9.1 Statistical Hypotheses
This is an exploratory study and no formal hypothesis testing w ill be performed.
9.2 Sample Size Determination
The sample size is not based on s tatistical power consideration s.
Approximately 10 subjects will be enrolled at 8 study centers for  study treatment. On Day 1,
subjects who meet all of the entry criteria will receive a 750 mg IV  dose of ANB019 in an 
open-label manner followed by 3 doses of 100 mg SC administered on Days 29, 57, and 85.
9.3 Populations for Analyses
For purposes of analysis, the analysis sets in Table 3 are defined .
Table 3 Analysis Sets
Full Analysis Set (FAS) The FAS analysis set will include all subjects, 
regardless of whether or not the treatment was 
received. Subjects will be analyzed according 
totreatment received.
Safety Analysis Set The Safety Analysis Set will include all 
enrolled subjects who receive at leas t 1 dose 
of ANB019. The Safety Analysis Set will be 
used for all safety analyses. Subjects will be 
analyzed according to treatment received.
Per Protocol Analysis Set (PPS) The Per Protocol analysis set will include all 
subjects in the FAS analysis set wh o do not 
have major protocol violations that would 
affect the evaluation of the primary efficacy endpoint.
PK Analysis Set The PK analysis set will include all subjects 
in the Safety Analysis S et who have at least [ADDRESS_294405] PK concentrations. The PK 
analysis set will be used for all PK analyses.
9.4 Statistical Analyses
The statistical analysis will be performed using statistical an alysis system (SAS®) Version 9.4 or 
higher if available. All details  regarding the statistical anal ysis and the preparation of tables, 
CONFIDENTIAL Protocol ANB019-002 –Amendment 5
29 October 2019 49listings and figures will be de scribed in the statistical analy sis plan (SAP). The SAP will be 
developed and finalized before da tabase lock and will describe the subject analysis sets to be 
included in the analyses, and procedures for accounting for mis sing, unused, and spurious data. 
This section is a summary of the pl anned statistical analyses o f the primary and secondary 
endpoints.
The default summary statistics for continuous variables include s number of contributing 
observations (n), mean, standard deviation (SD), median, minimum , and maximum. (See 
Section 9.4.7 for PK).
For categorical variables, the number and percentage (the perce ntage of subjects in each category 
relative to the total number of subjects in the relevant analysi s set or relative to the total number 
of subjects in the relevant analysis set, with assessments availa ble [where appropriate]) in each 
category will be the default summary presentation.
Unless otherwise specified, “ baseline ” is defined as the last obs erved value of the parameter of 
interest prior to the first intake of study drug (this includes unscheduled visits). For numerical 
variables, change from Baseline will be calculated as the differ ence between the value of interest
and the corresponding baseline value.
Point estimates will be accompanied with 2-sided 95% confidence interval (CIs), where 
applicable.
In the case of normality assumption violations, appropriate non -parametric methods will be used 
for analysis.
All data will be presented in by [CONTACT_85998].
9.4.[ADDRESS_294406] of protocol deviations/violations will be identified and discussed with the 
Investigator/AnaptysBio Inc. in dry-run to categorize as major or minor and the same will be 
reported.
9.4.[ADDRESS_294407] characteristics may include, but are not limited to age, gender, height, weight, 
and BMI.
CONFIDENTIAL Protocol ANB019-002 –Amendment 5
29 October 2019 50Summaries will include descri ptive statistics for continuous va riables (sample size [n], mean, 
SD, median, minimum, and maximum) and for categorical variables  (sample size, frequency, and 
percent).
Medical history will be coded using the Medical Dictionary for Regulatory Activities (MedDRA) 
dictionary latest version and listed for all subjects.
9.4.3 Concomitant Medication
All medications will be coded using the World Health Organizati on Drug Dictionary and 
Anatomical Therapeutic Chemical (ATC) system. Each medication wil l be classified as prior 
medication if it is stopped prior to the first dose of study dr ug, or as concomitant medication if it 
is ongoing at the time of the f irst dose or is started after th e first dose of study drug. Prior, 
concomitant and rescue medicati ons will be summarized by [CONTACT_242707] 2 categories and 
preferred name.
A listing of prior, concomitant, and rescue medications will be presented.
9.4.4 Efficacy Analyses
[IP_ADDRESS] Analysis of Primary Efficacy Endpoints
The primary efficacy endpoint is the proportion of subjects achiev ing clinical response at 
Weeks 4 and 16 . Clinical response is defined as “Very much improved”, “Much i mproved”, and 
“Minimally improved” on CGI s cale according to modified JDA severity index total score. The 
number and percentage of subjects achieving clinical response w ill be summarized in tabular 
form at Weeks 4 and 16. Each subjects CGI score will be plotted  at all study visits.
[IP_ADDRESS] Analysis of Secondary Efficacy Endpoints
Following are the secondary efficacy endpoints:
xChange in modified JDA severity index total skin lesions score (sum of erythema, erythema 
with pustules, edema) at all study visits.
Descriptive statistics will be pre sented at all study visits. Eac h subject ’s modified JDA severity 
index total skin lesion score will be plotted at all study visit s.
xChange in affected BSA of erythema with pustules, erythema, and edema as measured by 
[CONTACT_242708]:
Descriptive statistics will be generated at all study visits. An overlay plot of each subject’s value 
over all study visits will be generated for each component score .
xChange in total and individual scores in systemic manifestation s and laboratory findings as 
measured by [CONTACT_242709].
CONFIDENTIAL Protocol ANB019-002 –Amendment [ADDRESS_294408]’s value over all study visits 
will be generated for each measurement time.
xGPPPGA change from Baseline scores for all study visits.
xGPPPGA score at all study visits.
The GPPPGA will be summarized at each postbaseline visit for cha nge from Baseline scores and 
for the proportion of subjects achieving a GPPPGA score of [ADDRESS_294409]’s GPPPGA score for all study visits.
xChange in PASI score to evaluate a subject ’s overall PP disease state if present for all study 
visits:
Summary statistics will be provided for absolute PASI scores as  well as for percent change from 
Baseline for all study visits.
xChange in DLQI total score at all study visits:
Summary statistics will be provided for average DLQI scores, as w ell as for percent change from 
Baseline for all study visits.
9.4.5 Safety Analyses
xAssessment of AEs/SAEs (potentially significant and clinically important AEs, SAEs, and 
AEs leading to withdrawal)
xPhysical examinations
x12-lead ECG
xVital signs
xClinical safety laboratory tests (hematology, biochemistry, and  urinalysis).
All safety analyses will be perf ormed on the Safety Analysis Se t.
[IP_ADDRESS] Adverse Events and Serious Adverse Events
Treatment-emergent adverse  event: A TEAE is defined as:
xA new event that occurs during or after first dose of study treat ment or,
xAny event present at baseline that worsens in either intensity o r frequency after first dose of 
study treatment.
Only TEAEs will be summarized.
Adverse events will be coded using the MedDRA. Number of events a nd percentage will be 
tabulated by [CONTACT_82523]. An event th at occurred one or more times on 
treatment period for a subject will contribute 1 observation to th e numerator and denominator 
CONFIDENTIAL Protocol ANB019-002 –Amendment [ADDRESS_294410].
Summaries over SOC, PT and listings of TEAEs, TEAEs leading to de ath, SAEs, potentially 
significant TEAEs, clinically important TEAEs, and TEAEs that le d to discontinuation from the 
study or of the study drug will be presented. Summaries will also  be presented by [CONTACT_242710].
[IP_ADDRESS] Physical Examinations, 12-Lead ECG, Vi tal Signs and Clinical Safety Laboratory 
Tests (Hematology, Biochemistry, and Urinalysis)
Summaries and listings of data f or both limited and complete ph ysical examination findings, 
vital signs, hematology, biochemi stry, and urinalysis laboratory  tests will be presented. 
Appropriate descriptive statistics will be summarized for the o bserved value at each scheduled 
assessment and for the corresponding change from Baseline.
For hematology and biochemistry tests, listings of subject data w ill also flag up any abnormal or 
out-of-range values. Clinically significant changes in the labo ratory test parameters will be 
summarized and listed. Hematolo gy and clinical laboratory data will be reported in System 
International units.
Descriptive statistics will be used to present the safety outco mes including, physical examination 
results, weight, BMI, 12-lead ECG, vital signs measurements, and clinical laboratory test results.
Change from Baseline will also be summarized for vital signs measu rements, clinical laboratory 
test results.
All ECG data results (normal/abnormal) will be summarized using frequency and percentages. 
Clinically significant abnormalities will be presented in by [CONTACT_242711].
9.4.6 Immunogenicity Analyses
Observed values for ADA status/titers will be listed by [CONTACT_242712]. If data permits, a ny correlation between ADA status
and safety and efficacy endpoints will be evaluated.
CONFIDENTIAL Protocol ANB019-002 –Amendment 5
29 October 2019 539.4.7 Pharmacokinetic/Pharmacodynamic Analyses
[IP_ADDRESS] Derivation of Pharmacokinetic Parameters
The PK parameters will be derived using non-compartmental metho ds using the PK analysis set.
The actual sampling times will  be used in the PK parameter calc ulations. Further details of PK 
analysis, data handling, analysis procedures, and data reporting will be detailed in the SAP.
The following PK parameters will be determined for ANB019:xMaximum observed concentration (C
max).
xTime to maximum observed concentration (T max).
xArea under the curve (AUC).
Additional PK parameters may be determined if deemed appropriat e.
[IP_ADDRESS] Pharmacokinetic Concentration Data Analysis
A subject listing of all concentration-time data following stud y drug administration will be 
presented by [CONTACT_242713].
Concentration data of ANB019 will be summarized by [CONTACT_29303]/day and  nominal time point using
the number of observations (n), arithmetic mean, SD, coefficien t of variation (CV), minimum, 
median, maximum, and geometric mean.
Graphs for mean concentration-time data following IV administrat ion will be presented. 
Individual subject plots will  also be presented. Other presenta tions of data may be added at the 
discretion of the PK scientist , as appropriate, and will be des cribed in detail in the SAP.
[IP_ADDRESS] Pharmacokinetic Parameter Data Analysis
All PK parameters will be summarized using n, arithmetic mean, SD , CV, minimum, median, 
maximum, geometric mean, and geometric CV, with the exception of Tmax, which will be 
reported with n, minimum, median, and maximum only.
Graphs of parameters may be adde d at the discretion of the PK s cientist, as appropriate, and will 
be described in detail in the SAP.
9.4.[ADDRESS_294411] assessment before study treatment administration.
The relationship between ANB019 c oncentrations and biomarker en dpoints will be explored 
graphically.
CONFIDENTIAL Protocol ANB019-002 –Amendment [ADDRESS_294412] par ty (eg, a university 
Investigator) designated by [CONTACT_1034].
9.4.9 Missing Data
Missing data handling and possible sensitivity analysis will be  described in the SAP.
9.5 Interim and Final Analyses
An interim analysis will be perfor med when approximately 50% of subjects have completed their 
Week [ADDRESS_294413] reached 16 weeks p ostdosing. The interim analysis 
will assess primary efficacy and all safety data. Data from int erim analyses might be used as a
guideline for possible protocol modifications and planning of f uture clinical studies.
CONFIDENTIAL Protocol ANB019-002 –Amendment 5
29 October 2019 5510.0 REFERENCES
ANB019-001, AnaptysBio, San Die go, CA. A Double-Blind, Randomiz ed, Placebo-Controlled, 
Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) S tudy to Evaluate the 
Safety, Tolerability, Pharmac okinetics and Pharmacodynamics of ANB019 in Healthy Subjects 
and Psoriasis Patients. Cli nical Study Report; 22 June 2018.
Augey F, Renaudier P, and Nico las J-F. Generalized pustular psor iasis (Zumbusch): a French 
epi[INVESTIGATOR_242660]. Eur J Dermatol. 2006;16(6):669-73.
Bachelez H, Choon SE, Marrakchi S, et al. Inhibition of the IL-[ADDRESS_294414] for the Treatment of 
Generalized Pustular Psoriasis. N Engl J Med 2019; 380:(10).
Benjegerders K, Hyde K, Kivelevitch D, Mansouri B. Pustular pso riasis: pathophysiology and 
current treatment perspectives. Psoriasis (Auckl). 2016 Sep 12; 6:131-144.
Capon F. IL36RN mutations in generalized pustular psoriasis: just the tip of th e iceberg? J Invest 
Dermatol. 2013;133(11):2503-4.
Dubey JP, Markovits JE, and Killary KA. Cryptosporidim muris-li ke infection in stomach of 
cynomolgus monkeys (Macaca Fascicularis). Vet Pathol 2002;39(3) :363-71.
Fagerland, M. W., Hosmer, D. W., and Bofin, A. M. (2008). “Multinomial Goodness -of-Fit 
Tests for Logistic Regression Models.” Statistics in Medicine 27:4238 –4253.
Farthing MJ. Treatment options for the eradication of intestina l protozoa. Nat. Rev. Gastroent. 
Hepat. 2006;3:436-45.
Farooq M, Nakai H, Fujimoto A, Fujikawa H, Matsuyama A, Kariya N, et al. Mutation analysis 
of the IL36RN gene in [ADDRESS_294415] ular psoriasis. Hum. Mutat. 
2013;34:176-83.
Finlay AY, Kahn GK. Dermatology Life Quality Index (DLQI): A simp le practical measure for 
routine clinical use. Clinical and Experimental Dermatology. 199 4;19:210-6.
Fredriksson T, Pettersson U. Severe psoriasis-oral therapy with a new retinoid. 1978;157(4):238-
44.
Imafuku S, Honma M, Okubo Y, Komine M, Ohtsuki M, Morita A, et al. Efficacy and safety of 
secukinumab in patients with generalized pustular psoriasis: A 5 2 week analysis from phase 3 
open-label multicenter Japanes e study. The Journal of Dermatolo gy. 2016;43:1011-17.
Jordan C, Cao L, Roberson E, Pi[INVESTIGATOR_98803] K, Yang CF, Joyce CE, et al . PSORS2 Is Due to 
Mutations in CARD14. The American J of Human Genetics. 2012;90: 784-95.
CONFIDENTIAL Protocol ANB019-002 –Amendment [ADDRESS_294416] deficiency and gener alized pustular psoriasis. N. En gl. J. Med. 2011;365:620-8.
Marrakchi S, Burden A, Tsai T, et al. Inhibition of the Interle ukin-[ADDRESS_294417] for the Treatment 
of Generalized Pustular Psoriasis [To the Editor]. N. Engl. J. M ed. 2019; 380:[ADDRESS_294418] Dermatol. 2016;136:2251-59.
Navarini A, Burden A, Capon F, Mrowietz U, Puig L, Koks S. Euro pean consensus statement on 
phenotypes of pustular psoriasis. J Eur Acad Dermatol Venereol. 2017 Nov;31(11):1792-1799.
Ohkawara A, Yasuda H, Kobayashi H, Inaba Y, Ogawa H, Hashimoto I , et al. Generalized 
pustular psoriasis in Japan: Two distinct groups formed by [CONTACT_242714]. Acta Derm Venereol (Stockh).1996;76:68-71.
Oji V, Luger T. The skin in psor iasis: assessment and challenge s. Clin Exp Rheumatol. 2015;33 
(suppl. 93):S14-S19.
Onoufriadis A, Simpson M. A, Pi[INVESTIGATOR_8745] A. E, Di Meglio P, Smith C. H , Pullabhatla V, et al.
Mutations in IL36RN/IL1F5 are associated with the severe epi[INVESTIGATOR_242661]. Am. J. Hum. Genet. 201 1;89:432-7.
Sugiura K, Takeichi T, Kono M, Ogawa Y, Shimoyama Y, Muro Y, et  al. A novel 
IL36RN/IL1F5 homozygous nonsense mutation, p.Arg10X, in a Japan ese patient with adult 
onset generalized pustular psoriasis. Br. J. Dermatol. 2012;167 :699-701.
CONFIDENTIAL Protocol ANB019-002 –Amendment 5
29 October 2019 5711.0 APPENDICES
CONFIDENTIAL Protocol ANB019-002 –Amendment [ADDRESS_294419] Aspartate aminotransferase
ATC Anatomical Therapeutic Chemical
AUC Area under the concentration-time curve
BMI Body mass index
BSA Body surface area
CGI Clinical Global Impression
CI Confidence interval
Cmax Maximum observed concentration
CRF Case report form
CRP C-reactive protein
CSR Clinical Study report
CV Coefficient of variation
DLQI Dermatology Life Quality Index
DNA Deoxyribonucleic acid
DRE Disease-related events
ECG Electrocardiogram
eCRF Electronic case report form
EOS End of study
ET Early termination
FAS Full Analysis Set
FSH
GLPFollicle stimulating hormone
Good Laboratory Practices.
GPP Generalized pustular psoriasis
GPPPGA Generalized Pustular Psoriasis Physician’s Global Assessment
IB Investigator’s Brochure
ICF Informed consent form
ICH International Council for Harmonisation
CONFIDENTIAL Protocol ANB019-002 –Amendment [ADDRESS_294420] infection
WBC White blood cell
WOCBP Women of childbearing potential
CONFIDENTIAL Protocol ANB019-002 –Amendment 5
29 October 2019 60Appendix 2 Regulatory, Ethical, a nd Study Oversight Consideratio ns
Regulatory and Ethical Considerations
xThis study will be conducted in a ccordance with the protocol an d with the following:
Consensus ethical principles derived from international guideli nes including the 
Declaration of Helsinki and Council  for International Organizat ions of Medical 
Sciences (CIOMS) International Ethical Guidelines.
Applicable International Council for Harmonisation (ICH) GCP Guid elines.
Applicable laws and regulations.
xThe protocol, protocol amendments, ICF, Investigator Brochure, and other relevant 
documents (eg, advertisements) must be submitted to an IRB/IEC by [CONTACT_125485]/IEC before the study is initia ted.
xAny amendments to the protocol will require IRB/IEC and regulat ory authority approval, 
when applicable, before implemen tation of changes made to the s tudy design, except for 
changes necessary to eliminate an immediate hazard to subjects.
xThe Investigator will be responsible for the following:
Providing written summaries of the status of the study to the I RB/IEC annually or 
more frequently in accordance with the requirements, policies, and procedures 
established by [CONTACT_1201]/IEC.
Notifying the IRB/IEC of SAEs or other significant safety findi ngs as required by 
[CONTACT_1744]/IEC procedures.
Providing oversight of the conduct of the study at the study ce nter and adherence to 
requirements of 21 CFR, ICH guidelines, the IRB/IEC, European r egulation 536/2014 
for clinical studies (if appli cable), and all other applicable local regulations.
xAfter reading the protocol, each Investigator will sign the pro tocol signature [CONTACT_41452] a 
copy of the signed page to the Sponsor or representative. The stu dy will not start at any study 
center at which the Investigator has not signed the protocol.
Insurance
Sponsor will provide insurance in accordance with local guideli nes and requirements as 
minimum for the subjects in this study. The terms of the insura nce will be kept in the study files.
Informed Consent Process
xThe Investigator or his/her representative will explain the natu re of the study to the subject or 
his/her legally authorized representative and answer all questi ons regarding the study.
xSubjects must be informed that their participation is voluntary . Subjects or their legally 
authorized representative will be required to sign a statement o f informed consent that meets 
the requirements of 21 CFR 50, local regulations, ICH guideline s, Health Insurance 
CONFIDENTIAL Protocol ANB019-002 –Amendment [ADDRESS_294421] requirements, where applicabl e, and the IRB/IEC or study 
center.
xThe medical record must include a statement that written inform ed consent was obtained 
before the subject was entered i n the study and the date the wri tten consent was obtained. 
The authorized person obtaining the informed consent must also sign the ICF.
xSubjects must be re-consented t o the most current version of th e ICF(s) during their 
participation in the study.
xA copy of the ICF(s) must be provided to the subject or the subje ct’s legally authorized 
representative.
xSubjects who are rescreened are required to sign a new ICF.
The ICF will contain a separate section that addresses the use of remaining mandatory samples 
for optional exploratory research. The Investigator or authorize d designee will explain to each 
subject the objectives of the exploratory research. Subjects wi ll be told that they are free to 
refuse to participate and may withdraw their consent at any tim e and for any reason during the 
storage pe riod. A separate signature [CONTACT_22862] a subje ct’s agreement to allow 
any remaining specimens to be used for exploratory research. Su bjects who decline to participate 
in this optional research will not provide this separate signat ure.
Data Protection
xSubjects will be assigned a unique identifier by [CONTACT_1034]. A ny subject records or datasets 
that are transferred to the Sponsor will contain the identifier only; subject names or any 
information which would make the subject identifiable will not b e transferred.
xThe subject must be informed that his/her personal study related  data will be used by [CONTACT_19490]. The level of disclosure must also be 
explained to the subject.
xThe subject must be informed that  his/her medical records may be  examined by [CONTACT_242715], by 
[CONTACT_6667]/IEC members, and by [CONTACT_6668].
xThe ICF will incorporate (or, in some cases, be accompanied by a separate document 
incorporating) wording that complies with relevant data protect ion and privacy legislation.
xThe Sponsor or its representative will not provide individual g enotype results to subjects, any 
insurance company, any employer, their family members, general physician, or any other 
third party, unless required to do so by [CONTACT_2371].
xExtra precautions are taken to preserve confidentiality and pre vent genetic data being linked 
to the identity of the subject. In exceptional circumstances, h owever, certain individuals 
might see both the genetic data and the personal identifiers of  a subject. For example, in the 
case of a medical emergency, the Sponsor or representative phys ician or an Investigator
might know a subject ’s identity and also have acce ss to his or her genetic data. Al so 
regulatory authorities may require access to the relevant files .
CONFIDENTIAL Protocol ANB019-002 –Amendment [ADDRESS_294422]: 
Dissemination of Clinical Study Data
The results of the study should be  reported within 1 year from the end of the clinical study. 
Irrespective of the outcome, the Sponsor will submit to the EU d atabase a summary of the results 
of the clinical study within 1 ye ar from the end of the clinical  study. It shall be accompanied by a 
summary written in a manner that is understandable to layperson s.
Quality Control and Quality Assurance
According to the Guide lines of GCP (CPMP/ICH/135/95), is responsible for 
implementing and maintaining qua lity assurance and quality cont rol systems with written 
standard operating procedures ( SOPs ).Quality control will be applied to each stage of data 
handling .
The following steps will be taken to ensure the accuracy, consi stency, completeness, and 
reliability of the data:
xCentral laboratories for clin ical laboratory parameters.
xCenter Initiation visit.
xEarly center visits post-enrollment.
xRoutine center monitoring.
xOngoing center communication and training.
CONFIDENTIAL Protocol ANB019-002 –Amendment 5
29 October 2019 63xData management quality control checks.
xContinuous data acquisition and cleaning.
xInternal review of data.
xQuality control check of the final clinical study report (CSR).
In addition, Sponsor and/or  may conduct periodic 
audits of the study processes, including, but not limited to study center, central laboratories, 
vendors, clinical database, and final CSR .When audits are conducted, access m ust be authorized 
for all study related docu ments including medical history and concomitant medication 
documentation to authorized Sponsor’s representatives and regulatory authorities.
Monitoring
Sponsor has engaged the services of a contract research organization ,  to perform all 
monitoring f unctions within this clinical study . ’ monitors will work in accordance with 
SOPs . The monitor will establish and maintain regular contact [CONTACT_242716] .
The monitor will evaluate the com petence of the study center, inf orming Sponsor about any 
problems relating to facilities, technical equipment, or medical  staff. During the study, the
monitor will check that writte n informed consent has been obtain ed from all subjects correctly 
and that data are recorded correc tly and completely. The monito r is also entitled to compare 
entries in eCRFs with corresponding source data and to inform t he Investigator of any errors or 
omissions. The monitor will also assess and control adherence to t he protocol and ICH/GCP 
guidelines at the study center. T he monitor will arrange for the supply of study treatment, ensure 
proper study treatment dispensing/accountability, and appropria te storage conditions are 
maintained.
Monitoring visits will be conducted according to all applicable  regulatory requirements and 
standards. Regular monitoring visits will be made to each cente r while subjects are enrolled in 
the study.
During monitoring visits, all en tries in the eCRF s will be comp ared with the original source 
documents (source data verificati on). For the following and all other items, this check will be 
100%:
xSubject identification number.
xSubject consent obtained.
xSubject eligibility criteria (i nclusion and exclusion criteria).
xEfficacy variables.
xSafety variables.
xMedical record of AE.
Data Management/Coding
CONFIDENTIAL Protocol ANB019-002 –Amendment [ADDRESS_294423] ’s visit. To avoid inter-observer variability, every effort should 
be made to ensure that the same individual who made the initial baseline determinations 
completes all efficacy and safety evaluations. The Investigator must verify that all data entries in 
the eCRFs are accurate and correct. If some assessments are not  done, or if certain information is 
not available or not applicable or unknown, the Investigator sho uld indicate this in the eCRF. 
The Investigator will be required to electronically sign off on the clinical data.
The monitor will review the eCRF s and evaluate them for complet eness and consistency. The 
eCRF will be compared with the  source documents to ensure that there are no discrepancies 
between critical data. All entr ies, corrections and alterations  are to be made by [CONTACT_242717]/her designee. The monitor cannot enter data in the eCRFs. Once clinical data 
of the eCRF have been submitted to t he central server, correcti ons to the data fields will be audit 
trailed, meaning that the reason for change, the name [CONTACT_242736], 
together with time and date will be logged. Roles and rights of  the center staff responsible for 
entering the clinical data into the eCRF will be determined in advance. If additional corrections 
are needed, the responsible monitor or Data Manager will raise a query in the EDC application.
The appropriate study center staff will answer queries sent to the Investigator. This will be audit 
trailed by [CONTACT_242718], time and date 
stamp are captured.
The eCRF is essentially considered a data entry form and should  not constitute the original (or 
source) medical records unless otherwise specified. Source docu ments are all documents used by 
[CONTACT_192162][INVESTIGATOR_242662] ’s medical history, that ve rify the existence of
the subject, the inclusion and e xclusion criteria and all record s covering the subjec t’s 
participation in the study. They include but are not limited to  laboratory notes, ECG results, 
memoranda, pharmacy dispensing records, subject files, etc. Sourc e data should be attributable, 
legible, contemporaneous, original, accurate, and complete. Cha nges to source data should be 
traceable, should not obscure the original entry, and should be  explained if necessary (eg, via an 
audit trail).
CONFIDENTIAL Protocol ANB019-002 –Amendment [ADDRESS_294424] name, should be removed or rendered illegible to preserve individual 
confidentiality.
Electronic case report form records  will be automatically appen ded with the identification of the 
creator, by [CONTACT_5248]. Specified records wil l be electronically signed by [CONTACT_132157]/he r review of the data and acknowle dgement that the data are 
accurate. This will be facilitated by [CONTACT_132158] ’s unique User ID and password; 
date and time stamps will be added automatically at time of ele ctronic signature. If an entry on 
an eCRF requires change, the correction should be made in accor dance with the relevant 
software procedures. All changes will be fully recorded in a pr otected audit trail, and a reason for 
the change will be required.
Data Handling and Record Keepi[INVESTIGATOR_242663] (protoc ol and protocol amendments, 
completed eCRFs, signed ICFs, relevant correspondence, and all other supporting 
documentation). The study center should plan on retaining such documents for approximately 
[ADDRESS_294425] 2 years after the 
formal discontinuation of clinical development of the study tre atment (ANB019). These 
documents should be retained for a  longer period if required by  [CONTACT_202072][INVESTIGATOR_307], institution, or private practice in which the study is being 
conducted. Subject identificati on codes (subject names and corres ponding study numbers) will 
be retained for this same period of time. These documents may be transferred to another 
responsible party, acceptable to Sponsor, who agrees to abide b y the retention policies. Written 
notification of transfer must be submitted to Sponsor. The Inve stigator must contact [CONTACT_242719].
Direct Access to Source Documents
The Investigator will prepare and maintain adequate and accurate  source documents to record all 
observations and other pertinent data for each subject enrolled i nto the study.
The Investigator will allow Sponsor , , and authorized regulatory authorities to have direct
access to all documents pertaini ng to the study, including indi vidual subjec tmedical records, as 
appropriate. Such information must be kept confidential and must have locked facilities that 
CONFIDENTIAL Protocol ANB019-002 –Amendment [ADDRESS_294426] been collected and a study center closure visit has been perf ormed.
The Investigator may initiate study center closure at any time, p rovided there is reasonable cause 
and sufficient notice is given in a dvance of the intended termi nation.
Reasons for the early closure of a study center by [CONTACT_216594]:
xFailure of the Investigator to comply with the protocol, the req uirements of the IRB/IEC or 
local health authorities, the Sponsor ’s procedures, or GCP guidelines .
xInadequate recruitment of s ubjects by [CONTACT_737].
xDiscontinuation of further study treatment development.
Publication Policy
The data generated by [CONTACT_242720] o f the Sponsor. The Sponsor will 
make the results of the study publicly available. The publicati on policy with respect to the 
Investigator and study center will be set forth in the Clinical T rial Agreement.
CONFIDENTIAL Protocol ANB019-002 –Amendment 5
29 October 2019 67Appendix 3 Clinical Laboratory Tests
xThe tests detailed in Table 5 will be performed by [CONTACT_2237]. The time points are 
specified in Schedule of Activities (see Section 1.3).
xLocal laboratory tests will be allowed in the event that the ce ntral laboratory results will not 
be available immediately and the I nvestigator need to take an im mediate decision for any 
safety concerns. If a local samp le is required, it is important  that the sample for central 
analysis is obtained at the same time.
xUrine pregnancy dipstick will be performed at the study center p rior to study treatment 
administration.
xProtocol-specific requirements  for inclusion or exclusion of su bjects are detailed in 
Section 5.0of the protocol.
xAdditional tests may be performed at any time during the study as determined necessary by 
[CONTACT_9332].
Table 5 Protocol-required Safety Laboratory Assessments
Laboratory 
AssessmentsParameters
Hematology Hemoglobin Red Blood Cell Count
Hematocrit White Blood Cell Count (WBC) with 
Differential :
Neutrophils
Mean cell h emoglobin (MCH) Lymphocytes
Mean cell volume (MCV) Monocytes
Mean cell h emoglobin 
concentration (MCHC )Eosinophils
Platelet count Basophils
Clinical 
ChemistryAlanine Aminotransferase (ALT) Creatinine
Albumin Gamma glutamyl transferase (GGT)
Alkaline phosphatase (ALP) Glucose
Aspartate Aminotransferase (AST) Potassium
Bicarbonate Phosphate (Inorganic)
Bilirubin (Total) Protein (Total)
Bilirubin (Direct -only if total is 
elevated)Sodium
Calcium Blood urea nitrogen (urea)
Chloride Creatine Kinase (CK)
Uric acid Triglycerides
Lactate dehydrogenase human C -reactive protein (hCRP)
CONFIDENTIAL Protocol ANB019-002 –Amendment 5
29 October 2019 68Laboratory 
AssessmentsParameters
Troponin Total Cholesterol 
Serum pregnancy Human chorionic gonadotropin (hCG) pregnancy test (as needed for women 
of childbearing potential)
FSH Asneeded in women of non-childbearing potential only (Postmenopaus al 
woman aged over [ADDRESS_294427] 1 year of amenorrhea)
Urinalysis Bilirubin pH
Blood Protein
Glucose Specific gravity
Ketones Urobilinogen
Leukocytes Microbiology ( At discretion of 
Investigator based on urinalysis 
results )
Nitrite s Microscopy (At discretion of 
Investigator based on urinalysis 
results )
Viral serology Hepatitis B surface antigen
Hepatitis C Antibody
Human immunodeficiency virus
Antibodies
Tuberculosis 
(TB)screeningQuantiferon® - TB Gold In-tube, the third-generation test (If the te st 
indeterminate it can be retested only once)
NOTES: Please see Schedule of Activities (Section 1.3) for laboratory tests time points.
PK and ADA samples will be collected as detailed in the Schedule of Activities All blood samples 
must be drawn prior to administration of the study drug on Day 1. The date and exact time of 
sample collection must be recorded
Investigators must document their review of each laboratory saf ety report.
CONFIDENTIAL Protocol ANB019-002 –Amendment 5
29 October 2019 69Appendix 4 Adverse Events: Definitions and Procedures for Record ing, 
Evaluating, Follow-up, and Reporting
Definition of AE
AE Definition
xAn AE is any untoward medical occurrence in a subject or subjec t, temporally associated with the use 
of study treatment, whether or n ot considered related to the st udy treatment.
xNOTE: An AE can therefore be any unfavorable and unintended sig n (including an abnormal 
laboratory finding), symptom, or disease (new or exacerbated) t emporally associated wi th the use of 
study treatment.
Events Meeting the AE Definition 
xAny abnormal laboratory test results (hematology, clinical chem istry, or urinalysis) or other safety 
assessments (eg, ECG, radiological scans, vital signs measureme nts), including those th at worsen from 
baseline, considered clinically significant in the medical and scientific judgment of the Investigator (ie,
not related to progression of underlying disease).
xExacerbation of a chronic or intermittent pre-existing conditio n including either an increase in 
frequency and/or intensity of the condition.
xNew conditions detected or diagnosed after study treatment admi nistration even though it may have 
been present before the start of the study.
xSigns, symptoms, or the clinical sequelae of a suspected drug-d rug interaction.
xSigns, symptoms, or the clinical sequelae of a suspected overdo se of either study treatment or a 
concomitant medication. Overdose pe r se will not be reported as  an AE/SAE unless it is an intentional 
overdose taken with possible suicidal/self-harming intent. Such  overdoses should be reported 
regardless of sequelae.
x"Lack of efficacy" or "failure of expected pharmacological acti on" per se will not be reported as an AE 
or SAE. Such instances will be captured in the efficacy ass essments. However, the signs, symptoms, 
and/or clinical sequelae resulting from lack of efficacy will b e reported as AE or SAE if they fulfil the 
definition of an AE or SAE. 
Events NOT Meeting the AE Definition 
xAny clinically significant abnormal laboratory findings or othe r abnormal safety assessments which are 
associated with the underlying disease, unless judged by [CONTACT_242721] ’s condition.
xThe disease/disorder being stud ied or expected progression, sig ns, or symptoms of the disease/disorder 
being studied, unless more severe than expected for the subject ’s condition.
xMedical or surgical procedure (eg,  endoscopy, appendectomy): th e condition that leads to the 
procedure is the AE.
xSituations in which an untoward medical occurrence did not occu r (social and/or convenience 
admission to a hospi[INVESTIGATOR_307]).
xAnticipated day-to-day fluctuations of pre-existing disease(s) or condition(s) present or detected a t the 
start of the study that do not worsen.
CONFIDENTIAL Protocol ANB019-002 –Amendment [ADDRESS_294428] medical occurrence that, at an y dose:
a) Results in death
b) Is life-threatening
The term ‘life -threatening’ in the definition of “serious” refers to an event i n which the subject was at risk 
of death at the time of the event. It does not refer to an even t, which hypothetically might have caused 
death, if it were more severe.
c) Requires inpatient hospi[INVESTIGATOR_242664] g hospi[INVESTIGATOR_177257], hospi[INVESTIGATOR_5184] (usually involving at least an 
overnight stay) at the hospi[INVESTIGATOR_22771]/or treatment that  would not have 
been appropriate in the physician’s office or outpatient setting. Co mplications that occur during 
hospi[INVESTIGATOR_1084]. If a complication pro longs hospi[INVESTIGATOR_242665] s any other serious criteria, the 
event is serious. When in doubt as to whether “hospi[INVESTIGATOR_059]”  occurred or was necessary, the AE should 
be considered serious.
Hospi[INVESTIGATOR_5187] a pre -existing condition that did not worsen from baseline is not 
considered an AE.
d) Results in persistent disability/incapacity
xThe term disability means a substantial di sruption of a person’s ability  to conduct normal life 
functions.
xThis definition is not intended to include experiences of relat ively minor medical significance such as 
uncomplicated headache, nausea, vomiting, diarrhea, influenza, and accidental trauma (eg, sprained 
ankle) which may interfere with or prevent everyday life functi ons but do not constitute a substantial 
disruption.
e) Is a congenital anomaly/birth defect
f) Other situations:
xMedical or scientific judgment shoul d be exercised in deciding whether SAE reporting is appropriate 
in other situations such as important medical events that may n ot be immediately life- threatening or 
result in death or hospi[INVESTIGATOR_242666] 1 of the o ther outcomes listed in the ab ove definition. These events should 
usually be considered serious.
Examples of such events include invasive or malignant cancers, intensive treatm ent in an emergency 
room or at home for allergic bron chospasm, blood dyscrasias, or convulsions that do not result in 
hospi[INVESTIGATOR_059], or development of d rug dependency or drug abus e.
CONFIDENTIAL Protocol ANB019-002 –Amendment 5
29 October 2019 71Recording and Follow-up of AE and/or SAE
AE and SAE Recording
xWhen an AE/SAE occurs, it is the  responsibility of the Investig ator to review all documentation ( eg, 
hospi[INVESTIGATOR_1088], laborato ry reports, and diagnostics re ports) related to the event.
xThe Investigator will then record all relevant AE/SAE information in the CRF. Ea ch event must be 
recorded separately.
xIt is notacceptable for the Investigator to send photocopi[INVESTIGATOR_9238] ’s medical records to 
 Safety in lieu of completion of the /AE/ SAE CRF page.
xThere may be instances when cop ies of medical records for certa in cases are requested by 
 [CONTACT_242722] . In this case, all subject identifiers, with the exception of the subject number, will be 
redacted on the copi[INVESTIGATOR_242667] .
xThe Investigator will attempt to establish a diagno sis of the event based on sig ns, symptoms, and/or 
other clinical information. Whenever possible, the diagnosis (n ot the individual signs/symptoms) will 
be documented as the AE/SAE.
Assessment of Intensity
The Investigator will make an assessment of intensity for each AE and SAE report ed during the study and 
assign it to 1 of the following categories:
xMild: An event that is easily tolerated by [CONTACT_423] , causing minimal discomfort and not interfering 
with everyday activities.
xModerate: An event that causes sufficient discomfort and interferes with normal everyday activities.
xSevere: An event that prev ents normal everyday activities. An AE that is assessed as seve re should not 
be confused with a SAE. Severe is a category utilized for ratin g the intensity of an event; and both AEs 
and SAEs can be assessed as severe.
An event is defined as ‘serious’ when it meets at least 1 of the predefined outcomes as described in the 
definition of an SAE, NOT when it is rated as severe.
Assessment of Causality
xThe Investigator is obligated to assess the relationship between study treatment  and each occurrence of 
each AE/SAE. The AE must be ch aracterized as unrelated, possibl y related, and related.
o “Unrelated” clinical event with an incom patible time relationship to study drug
administration, and that could be explained by [CONTACT_242723]
o “Possibly related” Clinical event with a reasonab le time relationship to study dru g
administration, and th at is unlikely to be attributed t o concurrent condition or othe r drugs or 
chemicals
o“Related” Clinical event with pl ausible time relationship to study drug administration and that 
cannot be explained by [CONTACT_242724] t condition or other drugs or c hemicals
xThe Investigator will use clinical judgment to determine the rel ationship.
xAlternative causes, such as underlying disease(s), concomitant therapy, and other risk factors, as well 
as the temporal relationship of the event to study treatment ad ministration will be considered and 
investigated.
xThe Investigator will also consult the IB and/or Product Information, for marketed products, in his/her 
assessment.
xFor each AE/SAE, the Investigator must document in the medical notes that he/she has reviewed the 
AE/SAE and has provided an assessment of causality.
CONFIDENTIAL Protocol ANB019-002 –Amendment 5
29 October 2019 72xThere may be situations in which an SAE has occurred and the Investigator has minimal information to 
include in the initial report to  Safety . However, it is very important that the 
Investigator alwa ys make an assessment of causality for every event before the i nitial tra nsmission of 
the SAE data to  Safety .
xThe Investigator may change his/her opi[INVESTIGATOR_242668] t of follow- up information and send a 
SAE follow-up report with the updated causality assessment.
xThe causality assessment is one of the criteria used when deter mining regulatory reporting 
requirements.
Follow-up of AEs and SAEs
xThe Investigator is obligated to perform or arran ge for the conduct of supplemen tal measurements 
and/or evaluations as medically indicated or as requested by  [CONTACT_242725]/or causality of the AE or SAE as fully as possible. This may in clude additional laboratory 
tests or investigations, histopat hological examinations, or con sultation with other health care 
professionals.
xIf a subject dies during pa rticipation in the study , the Investigator will prov ide  Safety
with a copy of any post mortem findings.
xNew or updated information will be recorded in the originally c ompleted CRF.
xThe Investigator will submit any updated SAE data to the  Safety within 24 hours of 
receipt of the information.
Reporting of SAEs
SAE Reporting to  Safety via an Electronic Data Collection Tool
xThe primary mechanism for reporting an SAE to  Safety team will be the electronic 
data collection tool.
xIf the electronic system is unavailable for more than 24 hours,  then the study center will use the paper 
SAE data collection tool ( see next section).
xThe study center will enter the S AE data into the electronic sys tem as soon as it becomes available.
xAfter the study is completed at a given study center , the electronic data collection tool will be taken 
off-line to prevent the entry of  new data or changes to existin g data.
xIf a study center receives a report of a new SAE from a subject or receives updated da ta on a 
previously reported SAE after  the electronic data collection to ol has been taken off -line, then the study 
center can report this information on a paper SAE form (see next secti on) or (see next section) and 
send the paper SAE form to Safety team via facsimile transmission.
xContacts for SAE reporting can be found in SAE form.
SAE Reporting to  Safety via Paper CRF
xFacsimile transmission of the SAE paper CRF is the preferred me thod to transmit this information to 
the  Safety team .
xIn rare circumstances and in the absence of facsimile equipment , notification by [CONTACT_20021] a copy of the  SAE data collection tool sent by [CONTACT_22855].
xInitial notification via telephone does not replace the need fo r the Investigator to complete and sign the 
SAE CRF pages within the designated reporting time frames.
xContacts for SAE reporting can be found in SAE reporting form.
CONFIDENTIAL Protocol ANB019-002 –Amendment 5
29 October 2019 73Appendix 5 Excluded Medications/Therapy
Excluded medications/therapy is listed below. The use of an exc luded medication/therapy is a 
protocol violation and must be  recorded in the eCRF.
Any therapy likely to have efficacy in GPP or psoriasis is proh ibited. If treatment with any of 
these prohibited treatments is e ssential then the subject must n otify the study team and they will 
be withdrawn from the trial.
All treatments likely to have efficacy in GPP need to be discon tinued prior to treatment initiation 
(prior to Day 1) with washout periods as stipulated in Table 6.
A tapering washout of systemic therapi[INVESTIGATOR_014] (eg, cyclosporine, meth otrexate, and retinoids) can be 
used and the study drug can be i ntroduced before the end of the  washout period. Systemic 
conventional medications (eg, cyclosporine, methotrexate, and retin oids) must be stopped at the 
day the study drug has been administered.
Table [ADDRESS_294429] of Excluded Medications
Treatment Washout period
Topi[INVESTIGATOR_73201] (including cor ticosteroid, retinoids or vita min 
A or D analog preparations, tacrolimus, calcineurin inhibitor, topi[INVESTIGATOR_2855] H1 and H2 antihistamines,  tar preparations, keratolytic s, 
topi[INVESTIGATOR_166464], o ther medicated topi[INVESTIGATOR_12450]) or herb al 
preparation2weeks 
Methotrexate, cyclosporin, acitretin, alitretinoin, Fumaric acid  
esters, and corticosteroids or any other immunosuppressant or 
immunomodulating drugs4weeks 
Anti-tumor necrosis factor/interleukin (IL-12/IL-23) and IL- 17 or 
any other mAbs3months or 5 half -lives
Cyclophosphamide 6months
Phototherapy or PUVA 4 weeks 
Antibiotics and antivirals Topi[INVESTIGATOR_2855]: 2w e e k s
Systemic: 4w e e k s
Other investigational drugs 30days or 5 half- lives (whichever 
is longer) 
Live attenuated vaccines 3m o n t h s
Abbreviations: mAbs = monoclonal antibodies; PUVA = psoralen and u ltraviolet A.
CONFIDENTIAL Protocol ANB019-002 –Amendment 5
29 October 2019 74Appendix 6 Contraceptive Guidance and Collection of Pregnancy 
Information
Definitions:
Woman of childbearing potential (WOCBP)
A woman is considered fertile following menarche and until beco ming postmenopausal unless 
permanently sterile (see below).
If fertility is unclear (eg, amenorrhea in adolescents or athle tes) and a menstrual cycle cannot be 
confirmed before first dose of study intervention, additional e valuation should be considered.
Women in the following categories are not considered WOCBP
1. Premenarchal
2. Premenopausal female with 1 of the following:
xDocumented hysterectomy.
xDocumented bilateral salpi[INVESTIGATOR_1656].
xDocumented bilateral oophorectomy.
For individuals with permanent i nfertility due to an alternate medical cause other than the 
above, (eg, mullerian agenesis, a ndrogen insensitivity), Investi gator discretion should be 
applied to determining study entry.
Note: Documentation can come from the study center personnel’s: review of the subject ’s 
medical records, medical examina tion, or medical history interv iew.
3. Postmenopausal female:
xA postmenopausal state is defined as no menses for 12 months with out an alternative 
medical cause. A high follicle stimulating hormone (FSH) level in the postmenopausal 
range may be used to confirm a postmenopausal state in women no t using hormonal 
contraception or hormonal replacem ent therapy (HRT). However, i n the absence of 
[ADDRESS_294430] discontinue HR T to allow confirmation 
of postmenopausal status before study enrollment.
CONFIDENTIAL Protocol ANB019-002 –Amendment 5
29 October 2019 75Contraception Guidance
Male subjects
xMale subjects with female partners of childbearing potential ar e eligible to participate if they
agree to ONE of the following (during the protocol-defined time  frame in Section 5.1):
Are abstinent from penile-vaginal intercourse as their usual an d preferred lifestyle 
(abstinent on a long-term and pers istent basis) and agree to re main abstinent.
Agree to use a male condom plus partner use of a contraceptive method with a failure 
rate of <1% per year when having penile-vaginal intercourse with a  WOCBP who is 
not currently pregnant.
xIn addition, male subjects must refrain from donating sperm for  the duration of the study and 
for 220 days (which includes th e duration of relevant exposure p lus the duration of sperm 
cycle) after the last dose of study treatment.
xMale subjects with a pregnant or breastfeeding partner must agr ee to remain abstinent from 
penile-vaginal intercourse or use a male condom during each epi [INVESTIGATOR_242669] 220 days (which includes t he duration of relevant 
exposure plus the duration of sperm cycle) after the last dose of study treatment.
Female subjectsFemale subjects of childbearing potential are eligible to partic ipate if they agree to use highly 
effective methods of contraception consistently and correctly as  described in the table below.
CONFIDENTIAL Protocol ANB019-002 –Amendment 5
29 October 2019 76Highly Effective Contraceptive Methods
Highly Effective Contraceptive Methods That Are User Dependenta
Failure rate of <1% per year when  used consistently and correctly. 
Combined (estrogen and progestogen containing) hormonal contrac eption associated with inhibition of ovulation
xOral.
xIntravaginal.
xTransdermal.
Progestogen only hormonal contraception associated with inhibit ion of ovulation
xOral.
xInjectable.
Highly Effective Methods That Are User Independenta
Implantable progestogen only hormonal contraception associated with inhibition of ovulation
xIntrauterine device (IUD).
xIntrauterine hormone-releasing system (IUS).
Bilateral tubal occlusion .
Vasectomized Partner
A vasectomized partner is a highly effective birth control method provided that the partn er is the sole male sexual 
partner of the WOCBP and the absence of sperm has been confirmed. If not, an additional highly effective method 
of contraception should be used. 
Sexual Abstinence
Sexual abstinence is considered a highly effective method only if defined as  refraining fr om heterosexual 
intercourse during the entire peri od of risk associated with the study treatment. The relia bility of sexual abstinence 
needs to be evaluated in relatio n to the duration of the study a nd the preferred and usual lifestyle of the subject.
NOTES:
aTypi[INVESTIGATOR_20304]. Use should be consistent with 
local regulations regarding the use of contraceptive methods fo r subjects participating in clinical studies. 
Pregnancy Testing:
xWomen of childbearing potential should only be included after a confirmed menstrual period 
and a negative highly sensitive se rum pregnancy test at Screening and urine pregnancy test 
on Day 1 (prior to study treatment administration).
xWomen of childbearing potential should refrain from donating oo cytes for assisted 
reproduction during this period.
xAdditional pregnancy testing should be performed as mentioned in  the Schedule of Activities 
(see Section 1.3).
xPregnancy testing will be performed whenever a menstrual cycle is missed or when 
pregnancy is otherwise suspected. Positive urine pregnancy test result should be confirmed 
with serum test.
CONFIDENTIAL Protocol ANB019-002 –Amendment [ADDRESS_294431] ’s female 
partner who becomes pregnant while the male subject is in this s tudy. This applies only to 
male subjects who receive study treatment.
xAfter obtaining the necessary signed informed consent from the pregnant female partner 
directly, the Investigator will record pregnancy information on the appropriate pregnancy 
form and submit it to the Sponsor within 24 hours of learning of the partner’s pregnancy. The 
female partner will also be followed to determine the outcome o f the pregnancy. Information 
on the status of the mother and c hild will be forwarded to the Sponsor. Generally, the follow-
up will be no longer than 6 to 8 weeks following the estimated d elivery date. Any 
termination of the pregnancy w ill be reported regardless of fet al status (presence or absence 
of anomalies) or indication for the procedure.
Female subjects who become pregnant
xThe Investigator will collect pregnancy information on any female  subject who becomes 
pregnant while participating in this study. Information will be  recorded on the appropriate 
form and submitted to the Sponsor within [ADDRESS_294432]’s pregnancy.
xThe subject will be followed to determine the outcome of the pre gnancy. The Investigator
will collect follow-up information on the subject and the neona te and the information will be 
forwarded to the Sponsor. Generally, follow-up will not be requ ired for longer than 6 to 8 
weeks after the delivery date. A ny termination of pregnancy will  be reported, regardless of 
fetal status (presence or absence of anomalies) or indication f or the procedure.
xWhile pregnancy itself is not considered to be an AE or SAE, an y pregnancy complication or 
elective termination of a pregn ancy will be reported as an AE o r SAE. A spontaneous 
abortion is always considered to be an SAE and will be reported  as such.
xAny post-study pregnancy related SAE considered reasonably rela ted to the study treatment 
by [CONTACT_242726] i nS e c t i o n 8.3.5. While the 
Investigator is not obligated to actively seek this information in former subjects, he or she 
may learn of an SAE through spontaneous reporting.
xAny female subject who becomes pregnant while participating in the study will be withdrawn 
from the study.
CONFIDENTIAL Protocol ANB019-002 –Amendment 5
29 October 2019 78Appendix 7 Genetics
Use/Analysis of DNA/mRNA
xGenetic variation may impact a subject’s response to study treatment, susceptibility to, and 
severity and progression of disease. Variable response to study  treatment may be due to 
genetic determinants that impact drug absorption, distribution,  metabolism, and excretion; 
mechanism of action of the drug; di sease etiology; and/or molec ular subtype of the disease 
being treated. Therefore, where local regulations and IRB/IEC a llow, a blood sample will be 
collected for DNA analysis from consenting subjects.
xDNA/mRNA samples will be used to s tudy disease pathogenesis and to determine potential 
genetic biomarkers of response t o treatment. Genetic research m ay consist of the analysis of 
[ADDRESS_294433] conf identiality. Genetic 
analysis using DNA/mRNA samples may be performed by [CONTACT_168984] t hird party (eg, a 
university Investigator) designated by [CONTACT_1034]. The results  of genetic analyses may be 
reported in the CSR or in a separate study summary.
xThe samples may be retained while research on study treatment o r study treatments of this 
class or indication continue s as described in the ICF.
CONFIDENTIAL Protocol ANB019-002 –Amendment 5
29 October 2019 79Appendix 8 Clinical Global Impression
CategoryChange in modified 
JDA severity index total 
score for GPP and/or Category description
Very much improved Reduction by 3 or >points or Clear or almost clear of signs of GPP
Much improved Reduction by [ADDRESS_294434] one of the following:
xArea of erythema with pustules (%) 
reduced by <30%
or
xClinically meanin gful improvement 
in at least 2 other components of
the modified JDA severity index 
for GPP (area of erythema, area of 
edema, fever, WBC, CRP, Alb)
Minimally improved 0 points (no change) and At least one of the following:
xArea of erythema with pustules (%) 
reduced by <20%
or
xClinically meaningful improvement 
in at least 1 other components of 
the modified JDA severity index 
for GPP (area of erythema, area of 
edema, fever, white blood cell 
[WBC], C-reactive protein [ CRP],
Alb)
No change 0 points (no change) and Not meeting the other criteria of “minimally 
improved”
Worsened > + 1 point - Not applicable
CONFIDENTIAL Protocol ANB019-002 –Amendment 5
29 October 2019 80Appendix 9 Modified Japanese Derm atological Association (JDA) 
Severity Index
Score
0 1 2 3
Assessment of skin lesions
Area of erythema with pustules 0% > 0%, < 10% ≥ 10%, < 50% ≥ 50%
Area of erythema (total) 0% > 0%, < 25% ≥ 25%, < 75% ≥ 75%
Area of edema 0% > 0%, < 10% ≥ 10%, < 50% ≥ 50%
Assessment of systemic manifestations and laboratory findings
Fever<37oC
(<98.6 F)≥ 37oC, < 38.5oC
≥98.6 F, <101.3 F≥ 38.5oC
(≥101.3 F)_
WBC count<10,000/μL
(<10 × 109/L) ≥10,000/μL, <15,000 μL
(≥10 ×1 09/L, <15 × 109/L)≥15,000/μL
(≥15 ×1 09/L)_
CRP< 0.3 mg/dL
(<3 mg/L)≥ 0.3 mg/dL, < 7 mg/dL
(≥3mg/L, < 70 mg/dL)≥7mg/dL
(≥ 70 mg/dL)_
Serum albumin≥ 3.8 mg/dL
(≥ 38 g/L)< 3.8 g/dL, ≥3 mg/dL
(< 38 g/L, ≥ 30 g/L)< 3 m g/dL
(< 30 g/L)_
Severity index (total score): 1- 6=mild; 7-10=moderate; 11-17=se vere
The table is adapted from Imafuku S, Honma M, Okubo Y, Komine M , Ohtsuki M, Morita A, et 
al. Efficacy and safety of secukinumab in patients with general ized pustular psoriasis: A 52 week 
analysis from phase 3 open-label multicenter Japanese study. Th e Journal of Dermatology. 
2016;43:1011-1017.
CONFIDENTIAL Protocol ANB019-002 –Amendment [ADDRESS_294435] and severity of di sease at each study visit (ex cluding those that are phone calls) 
using the following scale.
Score Wording  Detailed description
[ADDRESS_294436] clear Faint, diffuse pi[INVESTIGATOR_242670], low density occasio nal 
small discrete pustules (noncoales cent), superficial focal scal ing 
or crusting restricted to periphery of lesions
2 Mild Light red erythema, moderate density grouped discrete small pustules (noncoalescent), predomin antly fine scaling or crustin g
[ADDRESS_294437] for the Treatment of Generalized Pustular Psoriasis. N Engl J Med 2019; 380:(10).
CONFIDENTIAL Protocol ANB019-002 –Amendment [ADDRESS_294438] WEEK. Please tick ;;one box for each question.
1.Over the last week, how itchy ,sore,painful orstinging has your skin been?
❏Very much ❏A lot ❏A little ❏Not at all
2. Over the last week, how embarrassed orself-conscious have you been because of your skin?
❏Very much ❏A lot ❏A little ❏Not at all
3. Over the last week, how much has your skin interfered with yo u going shoppi[INVESTIGATOR_242671] ?
❏Very much ❏A lot ❏A little ❏Not at all ❏Not relevant
4. Over the last week, how much has your skin influenced the clothes you wear?
❏Very much ❏A lot ❏A little ❏Not at all ❏Not relevant
5. Over the last week, how much has your skin affected any social orleisure activities?
❏Very much ❏A lot ❏A little ❏Not at all ❏Not relevant
6. Over the last week, how much has your skin made it difficult to do any sport?
❏Very much ❏A lot ❏A little ❏Not at all ❏Not relevant
7. Over the last week, has your skin prevented you from working orstudying ?
❏Yes ❏No❏not relevant
If "No", over the last week, how much has your skin been a prob lem at work or
studying ?
❏A lot ❏A little ❏Not at all
8. Over the last week, how much has your skin created problems w ith your partner or any of 
your close friends orrelatives ?
❏Very much ❏A lot ❏A little ❏Not at all ❏Not relevant
9. Over the last week, how much has your skin caused sexual difficulties ?
❏Very much ❏A lot ❏A little ❏Not at all ❏Not relevant
CONFIDENTIAL Protocol ANB019-002 –Amendment [ADDRESS_294439] week, how much of a problem has the treatment for your skin been, for 
example by [CONTACT_80243], or by [CONTACT_78469]?
❏Very much ❏A lot ❏A little ❏Not at all ❏Not relevant
AY Finlay, GK Kahn. Dermatology Life Quality Index (DLQI): A si mple practical measure for 
routine clinical use. Clinical and Experimental Dermatology 199 4; 19: 210-216.
CONFIDENTIAL Protocol ANB019-002 –Amendment 5
29 October 2019 85Appendix 13 Summary of Changes
Protocol ANB019-002: Amendment 1, 15 January 2018
Replaces: Original Protocol, 12 December 2017
Section 1.1 Synopsis, Section 4.1 Ove rall Design and Table 1 Sched ule of Activities (footnote)
xDescription of Change: Added text to indicate that a minimum [ADDRESS_294440] and s econd subcutaneous injections and d eleted from the following 
text‘no such limit for study center obs ervation after SC administrat ion’.
xPurpose of Change: Medicines and H ealthcare Products Regulatory  Agency (MHRA)
request.
Section 5.1 Inclusion Criteria and Appendix 6 Contraceptive Guida nce and Collection of Pregnancy 
Information:
xDescription of Change: Text revi sed to specify that in addition  to prohibition on sperm 
donation for the specified dura tion, ova donation for assisted reproduction is also prohibited. 
The duration for males was revised to 220 days (from 6 months).
xPurpose of Change: MHRA request.
Protocol ANB019-002: Amendment 2, 27 July 2018
Replaces: Amendm ent 1, 15 January 2018
Section 1.1 Synopsis and Section 4.1 Overall Design:
xDescription of Change: Text revised to remove a minimum of 7 days s creening period 
requirement and updated ‘up to 28 days’.
xPurpose of Change: To simplify enrollment of newly diagnosed su bjects.
xDescription of change: Updated  the number of Investigators and number of study centers 
from 3 to 5.
xPurpose of change: To reflect the updated number of Investigato rs and study centers 
(administrative change).
Section 2.2 Background (Clinical studies).
xDescription of Change: Added the pe rcentage for mild and moderat e TEAEs and details 
about 1 severe AE.
xPurpose of Change: To reflect th e updated Phase I Study results (ANB019-001, SAD part).
Section 2.2 Background and Section 2.3 Benefit/Risk Assessment:
xDescription of Change: Text revi sed to include SAD (PP) safety and MAD (healthy 
volunteers) safety and PK data from the Phase I study (ANB019-001) i n healthy volunteers 
and PP subjects.
xPurpose of Change: To reflect New safety and PK data from the Ph ase I study (ANB019-
001).
CONFIDENTIAL Protocol ANB019-002 –Amendment 5
29 October 2019 86Section 5.1 Inclusion Criteria:
xDescription of Change: Added SI and conventional units for hemogl obin, white blood cell 
count, platelets, and serum creatinine.
xPurpose of Change: To reflect both SI and conventional units for he moglobin, white blood 
cell count, platelets, and serum creatinine.
Section 5.2 Exclusion Criteria:
xDescription of Change: Text revi sed to clarify the requirement t o stop all systemic
conventional therapi[INVESTIGATOR_014] (eg. cyclosporine, methotrexate, and retin oid) the day the study drug 
is administered.
xPurpose of Change: To clarify the us e of systemic therapi[INVESTIGATOR_242672].
xDescription of Change: Revised t o remove definition of regular alcohol consumption and 
excessive smoking
xPurpose of Change: Text removed as definition is not applicable  in [LOCATION_008].
Section 5.3 1 Meals and Dietary Restrictions:
xDescription of Change: Removed Me als and Dietary Restrictions.
xPurpose of Change: Section remove d as study centers are not goin g to provide meal and
subjects are allowed to bring meal for themselves.
Section 6.2 Preparation /Handling/Storage/Accountability
xDescription of Change: Text re garding ANB019 storage reworded s lightly and deleted the 
repetitive text
xPurpose of Change: Sentence com bined to avoid repetition.
Section 6.5.1 Rescue Medicine:
xDescription of Change: Section rev ised to include guidance for using rescue medication in 
the form of topi[INVESTIGATOR_11930] (eg. betamethasone valerate  ointment and cream, 
mometasone furoate ointment and cream) and guidance for adding a ny systemic psoriasis 
medication that is likely to imp act psoriasis signs and symptom s (eg. cyclosporine, 
methotrexate, retinoid ).
xPurpose of Change: To provide clarity on rescue medication usag e.
xDescription of Change: Added text to indicate ‘ introduction of any rescue medication must 
be communicated and discussed with the Sponsor’ .
xPurpose of Change: To ensure that  use of rescue medication must  be communicated and 
discussed with the Sponsor.
Section 8.0 Study Assessments and Procedures.
Section 8.1.4 Total Body Surface Area (Study Assessments and Pro cedures).
xDescription of Change: Revis ed to remove the section 8.1.4 desc ribing assessment of body 
surface area affected by [CONTACT_242687].
CONFIDENTIAL Protocol ANB019-002 –Amendment 5
29 October 2019 87xPurpose of Change: Text removed as BSA involvement is measured as part of modified JDA 
scale.
Section 8.2.[ADDRESS_294441] X-ray and Table 1 Schedule of Assessment (foot note).
xDescription of Change: Bidirectional posterior-anterior and lateral view chest X-ray o r as 
indicated by [CONTACT_242727] t o include that it will be 
performed at Screening if not performed within 6 months prior to  screening and other 
time points specified in the  Schedule of Activities.
xPurpose of Change: To provide clarity on the time point of X-ra y.
xDescription of Change: Added text to indicate that ‘In case of early discontinuation, the 
subject will be encouraged to return to the study center for th e follow-up period visits 
(Week 16/Day 113 and Week 20/Day 141) a nd ET/EOS visit (Week 24/Day 1 69). The 
follow-up period visits are not act ual calendar weeks and have to occur 4/8/[ADDRESS_294442]-
discontinuation. ’
xPurpose of Change: To provide clarity in case of early disconti nuation and follow-up period 
(ET/EOS visit).
Section 8.3.7 Infusion-related adverse events:
xDescription of Change: Added text to indicate that a minimum [ADDRESS_294443] and s econd SC injections and deleted t he following text: “no such limit 
for study center observation a fter SC administration ”. In addition, text regarding IV 
administration modified to improve clarity.
xPurpose of Change: To provide de tails regarding duration of ass essment period after SC 
administration and text reworded for clarity.
Section 8.8 Biomarkers:
xDescription of Change: Storage duration of biomarkers sample were  updated to 5 years from 
1y e a r .
xPurpose of Change: To reflect the country specific storage requir ement.
Section 8.9 Immunogenicity assessment:
xDescription of Change: Immunogenic ity Sample storage time perio d updated from 1 to 5 
years.
xPurpose of Change: To reflect the country specific storage requ irement.
xDescription of Change: Added text to indicate that “only samples within the stability window 
of the assay will be analyzed ”.
xPurpose of Change: Updated to clarify that only the samples withi n the stability window of 
assay will be analyzed.
Appendix 2 Regulatory, Ethical, and Study Oversight Consideratio ns (Administrative Structure),
Medical Monitor.
xDescription of Change:  emergency contact [CONTACT_242728].
xPurpose of Change: Admin istrative change.
CONFIDENTIAL Protocol ANB019-002 –Amendment 5
29 October 2019 88Appendix 8 Signature [CONTACT_7919].
xDescription of Change: Protocol version updated to ‘Amendment 2’.
xPurpose of Change: Admin istrative change.
Additional changes in Table 1 Schedule of Activities:
xDescription of Change: Screeni ng period updated to include “up to 28 days.
xPurpose of Change: To simplify the  enrollment of newly diagnosed subjects.
xDescription of Change: Removed “total BSA”.
xPurpose of Change: Text removed as  BSA involvement is measured as part of modified JDA 
scale.
In addition, minor spelling, grammar, abbreviations, and format ting corrections have been made
Protocol ANB019-002: Amendment 3, 20 March 2019
Replaces: Amendm ent 2, 27 July 2018
Title Page:
xDescription of the change: Tit le page updated to reflect ‘Amend ment 3.’
xPurpose of the change: Administrative change.
Sponsor Signature [CONTACT_3490]:
xDescription of the change: Update d wording added to indicate Sp onsor’s responsibilities in 
signing the signature [CONTACT_3264]; re vised Sponsor signatory informati on
xPurpose of the change: To bette r align with the format in other  clinical program protocols.
Investigator Signature [CONTACT_3490]:
xDescription of the change: Move d the Investigator Signature [CONTACT_167554] e from Appendix [ADDRESS_294444] 
after the Table of Contents and updated wording to indicate Investigator’s responsibi lities in 
signing the signature [CONTACT_3264].
xPurpose of the change:  As requested by [CONTACT_242729].
Synopsis and Global
xDescription of the change: Forma tted references from superscrip t to author/year format to 
align with regulatory publication guidelines.
xPurpose of the change: To align w ith revised Anaptys Style Guid e.
xDescription of change: Updated  the number of Investigators and number of study centers 
from 5 to 8-10.
xPurpose of change: To reflect t he updated number of Investigator s and study centers 
(administrative change).
CONFIDENTIAL Protocol ANB019-002 –Amendment 5
29 October 2019 89Synopsis and Section 3:
xDescription of the change: Additional wording added to the seco ndary endpoints for PK 
analysis; moved immunogenicity objective (to assess ADA) from e xploratory to secondary 
endpoint; retitled tertiary/exploratory endpoints section to exploratory endpoints .
xPurpose of the change: To captur e an additional endpoint and to  better clarify the PK and 
pharmacogenomic testing; to place greater emphasis on immunogen icity testing.
xDescription of the change: Adde d an additional secondary endpoi nt to assess the proportion 
of subjects achieving a sc ore of [ADDRESS_294445] ular Psoriasis Physician’s 
Global Assessment scale.
xPurpose of the change: To furthe r characterize efficacy assessm ents for GPP.
Synopsis, Section 1.3 Schedule of Activities, and Section 4 Stud y Design
xDescription of the change: Revi sed the screening period from “u p to 28 days” to “up to 
42 days (Week -0 ).”
xPurpose of the change: To allow for more flexibility during the  screening period.
1.3 Schedule of Activities
xDescription of the change: A dded a row for whole blood collecti on for mRNA; added a 
footnote to clarify those study visits that were phone contact [INVESTIGATOR_13701]; rearranged order of 
footnotes
xPurpose of the change: To alig n with the additional PK endpoint  added in the synopsis and 
Section 3; to improve clarity on phone visits versus site visit s.
2.2 Background
xDescription of the change: Added a  reference in the text to a p reviously published CSR.
xPurpose of the change: To cite da ta that had been described in this section.
4 Study Design, 8.2.4 Pharmacokinetics
xDescription of the change: Adde d Table to detail the sample col lection and time points for 
PK and ADA testing
xPurpose of the change: To easily  identify collection times and visit requirements for PK and 
ADA testing.
5.1 Inclusion Criteria
xDescription of the change:
oRevised criterion #1 to increase  the upper age limit from 65 to  75.
oRevised criterion #3 regarding disease criteria for study entry  during the screening
period;
oRevised criterion #[ADDRESS_294446]
CONFIDENTIAL Protocol ANB019-002 –Amendment 5
29 October 2019 90xPurpose of the change:
oTo clarify requirements for subjec ts entering the study with re gards to JDA score and 
percentage of affected BSA;
oTo streamline and clarify procedures.
5.2 Exclusion criteria
xDescription of the change:
oCriterion #1: Removed 2 examples  of other forms of psoriasis th at were excluded 
from participation
oCriterion #17: Added a phrase that  history of drug and alcohol a buse and any 
potential impact on the ability to participate would be “determ ined by [CONTACT_3786].”
xPurpose of the change: To allow greater flexibility for eligibi lity.
6.5.1 Rescue Medication
xDescription of the change: Mi nor wording edits to this section regarding use of rescue 
medication and withdrawal of subjects.
xPurpose of the change: To improve text clarity and streamline d etails.
6.6 Dose Modification
xDescription of the change: Added w ording to clarify that study treatment may be interrupted 
only once before being permanently discontinued.
xPurpose of the change: To clarif y dose modification versus when  subjects should be 
withdrawn.
7.1 Discontinuation of Study Treatment
xDescription of the change: Revise d the wording of this section t o clarify discontinuation from 
treatment versus study and to be tter characterize subjects who are considered early 
termination.
xPurpose of the change: To alig n with common protocol template l anguage.
7.1.1 Temporary Interruption
xDescription of the change: Revi sed the heading title. Added som e additional text about 
recurring or new AEs related st udy treatment interruption.
xPurpose of the change: To clar ify guidelines for interruption o f study treatment and to 
specify that interruption woul d be allowed only once per subject .
7.1.2 Re-challenge
xDescription of the change: Added a  statement that this was not applicable.
xPurpose of the change: Details a bout restarting treatment that has been interrupted is 
covered in the previous section and this section is not needed;  however, a placeholder 
sentence was added t o cover this section.
CONFIDENTIAL Protocol ANB019-002 –Amendment 5
29 October 2019 918.1.4 Generalized Pustular Psoriasis Physician’s  Global Assessment Sc ale
xDescription of the change: New section added to describe the GP PPGA scale.
xPurpose of the change: T his assessment scale was added as a sec ondary endpoint to assess 
the impact of GPP at each study visit. Appendix 12 was also add ed to include the scale.
8.2.4 Electrocardiograms
xDescription of the change: Clarifie d that ECGs will be reviewed by [CONTACT_2237] 
“for quality and interpretation ” and that ECG data would not be entered into EDC with the 
exception of clinical significance.
xPurpose of the change: To re duce confusion over procedures and clarify the central lab’s role 
in ECG processing.
8.2.6 Photography
xDescription of the change: Langu age was revised to describe a s tandardized approach for 
collection of photographs and the process for transfer and qual ity review.
xPurpose of the change: To provide further guidance and clarity.
8.2.[ADDRESS_294447]
xDescription of the change: Added t his section to clarify the vi sits that are phone contact [CONTACT_242730].
xPurpose of the change: To clar ify visit purpose and procedures for phone contact.
8.5 Pharmacokinetics
xDescription of the change: Added Table [ADDRESS_294448] ion schedule for 
pharmacokinetic assessments during the study.
xPurpose of the change: To clar ify PK collection time points.
8.7 Genetics
xDescription of the cha nge: Revised language to characterize add itional DNA/RNA testing
and optional pharmacogenomic testing
xPurpose of the change: To align w ith revisions made to explorat ory endpoints for PK and 
pharmacogenomics
9.3 Populations for Analyses
xDescription of the change: Update d Table 3 to describe analysis  populations.
xPurpose of the change: To better align with the statistical ana lysis plan for this study.
9.4.4 Efficacy Analyses
xDescription of the change: A dded additional text to support the  added efficacy endpoint for 
the GPPPGA at Weeks 1 through 16.
xPurpose of the change: T o describe the analy sis associated with  this endpoint.
CONFIDENTIAL Protocol ANB019-002 –Amendment 5
29 October 2019 929.4.6 Immunogenicity Analyses
xDescription of the change: adde d description of how statistical  data will be presented
xPurpose of the change: Text adde d to better characterize the pr esentation of statistical data for 
ADA status and efficacy and safety endpoints
9.4.8 Biomarker Analyses
xDescription of the change: Remo ved the following sentences –Results will be presented in
terms of 95% CIs. In addition, the n, mean, SD, median, minimum  and maximum will also be 
prevented.
xPurpose of the change: To clarif y language in this section, as well as presentation of data.
10 References
xDescription of the change:
oAdded the following reference: A Double-Blind, Randomized, Placebo-Controlled, 
Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) S tudy to 
Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmac odynamics of 
ANB019 in Healthy Subjects and Psoriasis Patients. Protocol No.:  ANB019-001.
Clinical Study Report. 22 June 2018
oAdded the following reference: Bachelez H, Choon SE, Marrakchi S , et al. 
Inhibition of the IL-[ADDRESS_294449] for the Treatment of Generalize d Pustular 
Psoriasis. N Engl J Med 2019; 380:(10).
oAdded the following reference: Marrakchi S, Burden A, Tsai T, et  al. Inhibition of 
the Interleukin-[ADDRESS_294450] for the Treatment of Generalized Pus tular Psoriasis 
[To the Editor]. N. Engl. J. Med. 2019; 380:10.
xPurpose of the change:
oTo provide a citation for clinical trial data and information p rovided in Section 2.
oTo provide a citation for the GPPPGA scale in the objectives an d endpoints, as well 
as Appendix 11.
oTo provide a citation for the description of the GPPPGA scale i n Section 8.1.4.
Appendix 8 Signature [CONTACT_242737]: Remo ved this appendix and renumbered  remaining appendices.
xPurpose of the change: Moved t he Investigator’s signature [CONTACT_242738]’s signature [CONTACT_242739].
Appendix 11 Generalized Pustular Psoriasis P hysician’s Global Assessment
xDescription of the change:  New appendix was added.
CONFIDENTIAL Protocol ANB019-002 –Amendment 5
29 October 2019 93xPurpose of the change: To support  the added secondary endpoint of the GPPPGA assessment 
at each study visit.
In addition, minor spelling, grammar, abbreviations, editing, and  formatting corrections have 
been made throughout, as needed.
Protocol ANB019-002: Amendment 4, [ADDRESS_294451] 2019
Replaces: Amendm ent 3, 20 March 2019
Overall Rationale for the Amendment: 
This amendment was prepared to incorporate significant changes to the statistical methods section to 
characterize how the study endpoints would be analyzed, as well  as to modify the eligibility criteria and 
correct other inconsistencies within the text.
Global Changes
xDescription of the change: Minor edits applied for spelling and grammar, formatting, consistency, 
and spacing as needed.
xPurpose of the change: To clean-up for consistency, style, and formatting
Section 1.1 Protocol Synopsis, Section 3 Study Objectives
xDescription of the change: Revised the secondary objectives to r emove change from Baseline in 
GPPPGA score at all study visits and to assess change in Dermat ology Life Quality Index (DLQI) 
total score instead of improvement in DLQI total score at all v isits. Exploratory endpoint was 
revised for skin biopsies to assess IL-8 dendritic cells, not I L-6 dendritic cells. Removed 
references to logistic regression model using logit link.
xPurpose of the change: Statistical methods were revised to bett er characterize the proposed 
endpoints and goals of the study. The IL-[ADDRESS_294452] inconsistencies in the 
protocol.
Section 1.1. Synopsis
xDescription of the change: In the statistical methods section, a paragraph regarding the primary 
endpoint analysis was deleted.
xPurpose of the change: The discussion in the protocol is design ed to be more brief and concise, 
with full details provided in the SAP.
Section 1.3 Schedule of Activities
xDescription of the change: Footnote p was removed. Additional f ootnotes were moved and 
adjusted as needed on the schedule.
xPurpose of the change: To provide clarity and consistency in th e table.
Section 2.3 Benefit/Risk Assessment
xDescription of the change: Added one paragraph about an SAE of sepsis that has been reported 
during the study for [ADDRESS_294453].
CONFIDENTIAL Protocol ANB019-002 –Amendment 5
29 October 2019 94xPurpose of the change: To better characterize known safety issu es to date. This event was 
considered possibly related; the subject had a medical history of sepsis.
Section 5.1 Inclusion Criteria
xDescription of the change:
oCriterion 5 was removed which specified the enrollment of subje cts with or without a 
history of PP and PsA.
oCriterion 5 (formerly 6): a statement was added that any labora tory values that are out-of-
range at Screening will be left to the Investigator’s dis cretion as to whether or not a 
subject is eligible.
xPurpose of the change: To clarify permitted disease characteris tics of the study population. 
Subjects must have active diagnosis of generalized pustular pso riasis (GPP) and to allow greater 
flexibility fo r Investigator assessment after consultation with  Medical Moni tor and the 
Sponsor for determination of eligibility for out or range labor atory assessments
Section 5.2 Exclusion Criteria
xDescription of the change: Cri terion 13 was modified to include  squamous cell carcinoma 
deemed fully treatable by [CONTACT_242731].
xPurpose of the change: To clarify permitted disease characteris tics of the study population. 
Subjects must have active diagnosis of generalized pustular pso riasis (GPP) and to allow greater 
flexibility for Investigator assessment
Section 6.1 Study Treatments Administered, Table 1
xDescription of the change: Revised the table to clarify the lan guage around dose administration 
and to state that infusions may be slowed for subjects experien cing infusion-related reactions. 
Removed rows for packaging and manufacturing.
xPurpose of the change: To clarify the study treatment language and make the table more concise.
Section 6.7 Treatment After End of Study
xDescription of the change: Rev ised the statement on collection of AEs to include any occurring 
through End of Study (rather than 30 days after End of Study
xPurpose of the change: To clarify collection and timing of adve rse events.
Section 8.2.7 Clinical Safety Laboratory Assessments
xDescription of the change: Added a bullet to indicate that scre ening laboratory assessments that 
were out-of-range would be reviewed by [CONTACT_242732].
xPurpose of the change: To allow greater flexibility for Investi gator assessment and determination 
of eligibility for out or range laboratory assessments.
Section 8.5 Pharmacokinetics
xDescription of the change:
oAdded a paragraph to the text to indicate how samples will be c ollected and divided for 
primary and back-up analysis.
CONFIDENTIAL Protocol ANB019-002 –Amendment [ADDRESS_294454] begin immediately at the end of the infusion .
xPurpose of the change: For clarity on sample collection and doc umentation.
Section 8.8 Biomarkers
xDescription of the change: Revised the sentence on measurement o f skin biopsy markers to 
clarify that analyses may be performed by a third party. Revise d the language on blood sample 
collection to clarify the assay to be used. IL-[ADDRESS_294455] of biomarkers.
xPurpose of the change: To allow greater flexibility on sample a nalysis.
Section 8.9 Immunogenicity Assessments
xDescription of the change: Added a statement to clarify how ali quot samples will be divided. 
Removed a statement that clarified the length of time for sampl e storage.
xPurpose of the change: To provide clarity on sample collection procedures.
Section 9.3 Population for Analyses, Table 3
xDescription of the change: Removed the ITT Analysis Set and rep laced with Full Analysis Set 
(FAS) in the table. Removed any references to randomization. The PPS will now be based on the 
FAS instead of the ITT set.Additional text was added to clarify  use of the PK analysis set.
xPurpose of the change: This is an open-label study. All enrolle d subjects will be analyzed 
according to treatment received.
Section [IP_ADDRESS] Primary Efficacy Endpoint Analyses
xDescription of the change: Added a clarification on the analysi s of clinical response and Clinical 
Global Impression (CGI) score. Deleted detailed text on statisti cal analysis as it will be moved to 
the SAP.
xPurpose of the change: For clarity on statistical analysis pres entation.
Section [IP_ADDRESS] Secondary Efficacy Endpoint Analyses
xDescription of the change:
oClarified that secondary endpoints will be analyzed at all study  visits through Week 16 
for modified JDA severity index score, descriptive statistics, GPPPGA score, and PASI 
score. Deleted detailed text on sta tistical analysis as it will  be moved to the SAP.
oIncluded a statement that summary statistics will be provided f or average DLQI scores 
instead of absolute scores, in addition to the percent change f rom Baseline through Week 
16 instead of by [CONTACT_15449].
xPurpose of the change: For grea ter clarity on secondary endpoin t analysis.
Section [IP_ADDRESS] Derivation of PK Parameters
CONFIDENTIAL Protocol ANB019-002 –Amendment 5
29 October 2019 96xDescription of the change: Clarified that PK parameters will be  analyzed using the PK analysis 
set.
xPurpose of the change: For clarity of analysis description.
Section [IP_ADDRESS] Pharmacokinetic Concentrations
xDescription of the change: Removed the trough concentrations fr om plots.
xPurpose of the change: For clarity of PK analysis.
Section 9.4.8 Exploratory Biomarker Analyses
xDescription of the change: Added additional text to clarify the  analysis of exploratory biomarkers 
and how their relationship to ANB019 concentrations will be cha racterized .
xPurpose of the change: For grea ter clarity on exploratory analy ses objectives and goals.
Section 9.5 Interim and Final Analyses
xDescription of the change: Added a paragraph to clarify the timin g of interim analysis for this 
study.
xPurpose of the change: Administrat ive change to clarify interim  and final analyses for this study.
Appendix 1 Abbreviations
xDescription of the change: Abbreviations added or removed to al ign with usage following edits 
for amendment 4.
xPurpose of the change: Administrative
Appendix 2 Regulatory, Ethical, and Study Oversight
xDescription of the change: Revised Table 4 to clarify study roles between  and Anaptys
xPurpose of the change: For clarity on study administrative struc ture.
Appendix 7 Genetics
xDescription of the change: Clarified when mRNA will be analyzed . Deleted text regarding the 
duration of retention of samples.
xPurpose of the change: to align w ith analysis of DNA samples. Th e duration of sample retention 
is specified in the ICF.
CONFIDENTIAL Protocol ANB019-002 –Amendment 5
29 October 2019 97Protocol ANB019-002: Amendment 5, 29 October 2019
Replaces: Amendment 4, [ADDRESS_294456] 2019
Overall Rationale for the Amendment: 
This amendment was prepared to comply with a request from the M edicines and Healthcare Products 
Regulatory Agency to remove the flexibility for Investigators t o discuss eligibility for those patients who 
do not meet screening laboratory eligibility criteria.
Global Changes
xDescription of the change: Minor edits applied for formatting and consistency.
xPurpose of the change: Administrative
Section 5.1 (Inclusion Criterion #5) and Section 8.2.7 Clinical Sa fety Laboratory Assessments
xDescription of the change: The sentence permitting the Investiga tor to assess eligibility in 
consultation with the Medical Monitor and the Sponsor, for those  subject who fail to meet 
laboratory screening criteria, has been removed.
xPurpose of the change: To remove this flexibility for subject en rollment and to comply with the 
Medicines and Healthcare Products Regulatory Agency request.